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Abstract 
CD4+CD25++Foxp3+ regulatory T cells (Treg) actively control self-reactive 
conventional T cells (Tcon) and other cell types and thus maintain peripheral 
tolerance. Accordingly, an imbalance with regard to quantity or quality of Treg-
mediated suppression can lead to various immune pathologies, e.g. autoimmune 
diseases. The elucidation of mechanisms that influence Treg numbers remains 
therefore a major challenge for the establishment of therapies.  
Recent in vitro and in vivo data point to the death receptor CD95 (APO-1/Fas) and its 
ligand CD95L (CD178/APO-1L/FasL) as one potential system in the control of Treg 
numbers. In an in vitro T cell death model, freshly isolated Tcon are CD95-resistant. 
However, after an in vitro expansion of 6 days they upregulate CD95 and start 
producing CD95L upon T cell antigen receptor (TCR) re-stimulation. Subsequent 
binding of endogenous CD95L to CD95 leads to suicide/fratricide via a process called 
activation-induced cell death (AICD). In contrast to Tcon, day 0 as well as day 6 Treg 
are highly sensitive to CD95-induced apoptosis but do not undergo AICD upon TCR 
re-stimulation.  
In the present work two points regarding the apoptosis of Treg were investigated. 
First, the molecular basis for the lack of AICD in Treg was examined. Second, the 
sensitivity of Treg towards CD95-mediated apoptosis was analyzed in vivo.  
Concerning the first part, one plausible explanation for the lack of AICD in Treg is 
insufficient CD95L expression. Indeed, the investigation of CD95L levels in Treg upon 
stimulation revealed that they express, compared to Tcon, less CD95L mRNA as well 
as protein. This diminished CD95L expression is neither due to altered kinetics nor 
caused by CD95L cleavage. Low CD95L expression occurs irrespective of the cellular 
activation status, although the Treg population consists, in contrast to Tcon, mainly of 
effector/memory cells. In the second part, the sensitivity of Treg to CD95-induced 
apoptosis was investigated in vivo. CD95-deficient bone marrow chimeric mice 
containing CD95+ T cells tolerate CD95 stimulation. In this mouse model, injection of 
an agonistic anti-CD95 antibody resulted in reduced Treg numbers in vivo.  
In conclusion, the resistance of Treg to AICD in vitro can be attributed to low 
stimulation-induced CD95L expression. Furthermore, the data demonstrate that Treg 
are sensitive to CD95-induced apoptosis in vivo. This apoptosis sensitivity might be 
exploited by CD95L+ Tcon to eliminate Treg by CD95 stimulation for the 
establishment of powerful immune responses. Altogether, the presented findings 
contribute to the understanding of the mechanisms which control Treg homeostasis.  
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Zusammenfassung 
CD4+CD25++Foxp3+ regulatorische T-Zellen (engl. Treg) kontrollieren selbstreaktive 
konventionelle T-Zellen (engl. Tcon) und andere Zellarten und Erhalten dadurch die 
periphere Toleranz. Demzufolge kann ein Ungleichgewicht hinsichtlich Quantität oder 
Qualitiät der Treg-vermittelten Hemmung zu verschiedenen Immunpathologien, z.B. 
Autoimmunität, führen. Die Aufklärung der Mechanismen, die die Treg-Anzahl 
beeinflussen, bleibt daher eine große Herausforderung zur Etablierung von Therapien. 
Kürzlich gewonnene in vitro und in vivo Daten lassen auf den Todesrezeptor CD95 (APO-
1/Fas) und seinen Liganden CD95L (CD178/APO-1L/FasL) als ein potentielles System 
bei der Kontrolle der Treg-Anzahl schließen. In einem in vitro T-Zell Todesmodell sind 
frisch isolierte Tcon CD95-resistent. Nach einer 6-tägigen in vitro Expansion erhöhen sie 
die CD95 Expression und beginnen nach Restimulierung des T-Zell Antigenrezeptors 
(engl. TCR) mit der Produktion des CD95L. Anschließendes Binden des endogenen 
CD95L an CD95 führt zu Suizid/Fratrizid durch den Prozess des aktivierungsinduzierten 
Zelltods (engl. AICD). Im Gegensatz zu Tcon sind Tag 0 und auch Tag 6 Treg 
hochsensitiv gegenüber CD95-induzierter Apoptose, zeigen aber keinen AICD nach TCR 
Restimulierung.  
In der folgenden Arbeit sollen zwei Punkte hinsichtlich der Apoptose von Treg 
untersucht werden. Zuerst soll die molekulare Basis für das Fehlen des AICD in Treg in 
vitro betrachtet werden. Zweitens soll die Sensitivität von Treg gegenüber CD95-
vermittelter Apoptose in vivo untersucht werden.  
Für den ersten Teil ist eine ungenügende CD95L Expression eine plausible Erklärung für 
den fehlenden AICD bei Treg. Tatsächlich zeigte die Untersuchung der CD95L Menge in 
Treg nach Stimulierung, dass sie, verglichen mit Tcon, wenig CD95L mRNA und auch 
Protein exprimieren. Die niedrige CD95L Expression ist weder bedingt durch eine 
veränderte Kinetik, noch verursacht durch CD95L Spaltung. Auch spielt der zelluläre 
Aktivierungsstatus keine Rolle, obwohl Treg, im Gegensatz zu Tcon, hauptsächlich 
Effektor-/Gedächtnis-Zellen sind. 
Im zweiten Teil wurde die Sensitivität von Treg gegenüber CD95-induzierter Apoptose 
mithilfe eines Mausmodells in vivo untersucht. CD95-defiziente knochenmarkchimäre 
Mäuse, die CD95+ T-Zellen enthalten, zeigen nach CD95-Stimulierung kein 
Leberversagen. Injektion eines agonistischen anti-CD95 Antikörpers reduzierte die 
Anzahl der Treg in vivo.  
Zusammenfassend kann die Resistenz von Treg gegenüber AICD in vitro einer niedrigen 
stimulierungsinduzierten CD95L Expression zugeschrieben werden. Des weiteren zeigen 
die Mausmodell-Daten, dass Treg in vivo sensitiv gegenüber CD95-induzierter Apoptose 
sind. Diese Apoptosesensitivität könnte durch CD95L+ Tcon ausgenutzt werden, Treg 
durch CD95 Stimulierung zu eliminieren, um leistungsstarke Immunantworten zu 
generieren. Insgesamt tragen diese Ergebnisse zum Verständnis der Mechanismen, die die 
Treg Homeostase kontrollieren bei. 
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1  Introduction 
1.1 The immune system 
The immune system (lat.: immunis – pure) of higher organisms is a biological defense 
system that recognizes and antagonizes pathogens to prevent diseases. As a complex 
network of organs, cell types and molecules it is able to distinguish the organism’s 
healthy cells from a wide variety of dangerous structures (bacteria, viruses, fungi, 
protozoa and diseased/damaged cells) and can therefore identify and eliminate 
foreign microorganisms and altered body cells.  
1.1.1 Innate and adaptive immunity  
The immune system consists of two parts: the innate and adaptive immune system are 
linked to each other but differ in their components and function. While the innate 
immune system reacts very fast upon encounter of pathogens, the adaptive immune 
system adjusts over time to eliminate pathogens more efficiently and has the property 
of immunological memory. However, only the coordinated interplay of the various 
components of both parts allows for the complex immune reactions of the body.  
The innate immunity consists of anatomical and physiological barriers, cell-mediated 
phagocytosis, general inflammatory reactions and the complement system. The front 
line barriers against infection are the epithelia (skin and gastrointestinal, respiratory 
and urogenital tract) which protect the body against pathogens by their compact 
structure and via the production of mucus and microbicidal substances. The 
recognition of pathogens by macrophages, natural killer (NK) cells and neutrophils 
with germ-line encoded receptors represents the next line of defense. Among their 
receptors are the toll-like receptors (TLR) which detect extracellular as well as 
intracellular pathogenic features. Invariable properties of pathogens, the so-called 
pathogen-associated molecular patterns (PAMP), are recognized by these receptors. 
For instance, some cells destroy the pathogenic agent themselves while others set the 
body in an alarm position by the production of messengers (interleukins) to enhance 
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the immune reaction. Furthermore, the complement system, a network of various 
plasma proteins which is distributed throughout body fluids and tissues, is activated 
at sites of infection by a proteolytic enzyme cascade. Complement proteins protect 
against infection in three ways: by opsonizing pathogens for engulfment, through 
chemoattractants to recruit phagocytes and via the creation of pores in the pathogen’s 
membrane (Liszewski et al., 1996). 
The second part of the immune system, the adaptive immunity, is characterized by 
the capability to adjust to new or modified pathogenic structures. Antigen-presenting 
cells (APC) like dendritic cells (DC) digest invading pathogens and present pathogen-
derived peptides which are recognized by antigen (Ag) receptors of lymphocytes 
which then establish a directed defense mechanism. Lymphocytes are divided into 
bone marrow (BM)-derived (B) lymphocytes which are responsible for the humoral 
immunity that uses antibodies as effector molecules and thymus-derived (T) 
lymphocytes that enable a cell-mediated immune response and support B 
lymphocytes. T cells can discriminate self from non-self by the so-called major 
histocompatibility complex (MHC) which is displayed on each cell of the body. 
Diseased cells that present pathogenic peptides on MHC molecules are recognized 
and become a target of lymphocytes. To be highly adaptable, the Ag receptor genes of 
T and B cells undergo recombination of their so-called V(D)J elements and in the case 
of the B cell Ag receptor complete a process of somatic hypermutation. These two 
mechanisms allow for the generation of large amounts of different Ag receptors by a 
restricted gene repertoire, which are then uniquely expressed on individual 
lymphocytes. During an immune response, lymphocytes with the required receptor 
specificity expand and give rise to a large population of effector lymphocytes that 
clear the pathogen. After a resolved infection, memory cells and specific antibodies 
remain which facilitate a quick reaction upon second encounter with the same 
pathogen.  
Disorders of the immune system can result in disease. A compromised immune 
system leads to immunodeficiency causing recurrent and life-threatening infections 
which can be either genetically inherited (e.g. severe combined immunodeficiency 
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(SCID)), triggered by pharmaceuticals (e.g. glucocorticoids) or induced by infection 
(e.g. acquired immune deficiency syndrome (AIDS)). In contrast, autoimmune 
diseases occur when the immune system is hyperactive and attacks normal tissues as 
if they were foreign organisms. Examples for autoimmune diseases are rheumatoid 
arthritis, type 1 diabetes and lupus erythematosus. 
1.1.2 T lymphocyte development  
While B lymphocyte maturation takes place in the BM, hematopoietic progenitor cells 
migrate from the BM to the thymus for the generation of the T cell pool. In mice, the 
thymus continues to develop for 3-4 weeks after birth, which is in contrast to humans 
who are born with a fully developed thymus. Upon arrival in the thymus, thymocytes 
go through a precise screening procedure for their T cell Ag receptor (TCR), the 
positive and negative selection, to ensure immunogenic competence and diversity 
without self-reactivity. Approximately 98% of thymocytes die during the 
developmental differentiation process by failing either positive or negative selection, 
whereas the other 2% survive to give rise to T cells.  
The intrathymic developmental stages of T cell progenitors can be characterized by 
their temporally coordinated expression of cell surface markers, e.g. the cluster of 
differentiation (CD) 3 complex, the co-receptors CD4 and CD8 as well as CD25 and 
CD44 (Godfrey et al., 1993). Neither CD4 nor CD8 are expressed by thymocytes in the 
earliest developmental stages which are therefore classed as double negative (DN) 
pre-T cells (Vonboehmer, 1988). During maturation, DN thymocytes give rise to two 
distinct T cell lineages which express different TCR chains. The majority are : T cells 
which express TCR:TCR chains, while only a small percentage of cells become 
TCR:TCR positive. The : T cells remain CD4/CD8 negative and will not be 
discussed further. The development of : T cells will be described in more detail.  
During four DN stages which can be distinguished by the differential expression of 
CD25 and CD44, thymocytes rearrange the gene for the TCR chain which pairs with 
a surrogate pre-TCR chain. Expression of the resulting pre-TCR together with the 
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signal transducing CD3 complex leads to cell proliferation and the expression of CD4 
and CD8. Due to their expression of both CD4 and CD8, these cells are called double 
positive (DP) thymocytes. 
DP thymocytes rearrange the TCR chain locus and start to express the complete TCR 
consisting of the two TCR chains and the CD3 complex. They move deeper into the 
thymic cortex where they are positively selected on cortical thymic epithelial cells 
(TEC). In this selection process, thymocytes with TCR complexes that are able to bind 
to self-Ag presented on MHC molecules with adequate affinity receive a survival 
signal. DP cells that are positively selected on MHC class II molecules stop to express 
CD8 and become CD4+ cells, while cells positively selected on MHC class I molecules 
mature into CD8+ cells. Developing thymocytes that cannot bind to Ag/MHC or bind 
with only very low affinity die by apoptosis and are rapidly phagocytosed (feeney et 
al., 1994; Mizuochi et al., 1992). Thymocytes that bind Ag/MHC with too high affinity 
become apoptotic by negative selection in the medulla with the help of medullary 
TEC which ensures tolerance to self-peptides (Petrie et al., 1990; Saintruf et al., 1994; 
Shortman and Wu, 1996). To enable T cell tolerance to a wide variety of self-Ag, the 
transcription factor (TF) autoimmune regulator (AIRE) allows medullary TEC to 
express proteins specific for other tissues in the thymus. Thereby, autoreactive T cells 
against  various tissue Ag can be deleted in the thymus (Derbinski et al., 2001). Mature 
T cells that have accomplished the stringent selection processes in the thymus are 
released into secondary peripheral lymphatic tissues.  
1.1.3 T-cell mediated immune responses 
The process of somatic recombination leads to a large TCR variablity and inevitably to 
a small number of T cells with a particular TCR specificity. During an immune 
response against a certain pathogen, T cells with the required specificity are activated 
to proliferate and differentiate. Specialized APC like B cells, macrophages and most 
importantly DC are able to activate T cells (Inaba et al., 1990). Immature DC reside in 
tissues where they are in contact with invading pathogens, e.g. in the skin, in the 
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respiratory tract, in the blood and in the lymphatic system (Maldonado-Lopez and 
Moser, 2001). Detection of PAMP via various receptors (i.a. Fc- and complement 
receptors or TLR) by DC stimulates them to mature and migrate to lymphatic organs 
(Guermonprez et al., 2002; Janeway and Medzhitov, 2002; Matzinger, 1994; Caux et al., 
1994). Mature DC which express high levels of MHC and co-stimulatory B7 family 
members (mostly CD80 and CD86) efficiently stimulate naïve T cells by the 
presentation of pathogenic peptide fragments complexed with MHC molecules 
(Trombetta and Mellman, 2005). An intracellular signaling cascade in the T cell upon 
binding of the TCR to Ag/MHC leads to activation and proliferation (Gascoigne and 
Zal, 2004; van Leeuwen and Samelson, 1999). For naïve T cells, the TCR signal must be 
complemented with a co-stimulatory signal delivered by CD28 on T cells upon 
interaction with CD80 and CD86 on DC. In the absence of this second signal, ligation 
of the TCR leads to T cell inactivation and anergy (Greenwald et al., 2005; Macian et 
al., 2004).  
T cells can be grouped into CD8+ cytotoxic T cells and CD4+ T cells. Depending on the 
type of pathogen and the site of the immune response, CD4+ T cells differentiate into 
distinct T cell subsets. The two major categories of CD4+ T helper cells, characterized 
by their cytokine profile, are T helper 1 (Th1) and Th2 cells. Th1 cells support CD8+ T 
cells to eliminate infected cells while Th2 cells provide help to B cells for the 
production of antibodies (Abbas et al., 1996). In the intestine, pro-inflammatory Th17 
cells are the major CD4+ T cell subset (Bettelli et al., 2008). In addition, a small 
percentage of CD4+ T cells form the regulatory T cell (Treg) lineage. This T cell subset 
will be discussed in detail in chapter 1.3.  
1.2  Programmed cell death 
The first observations that described cell death were made 200 AD by Galenus Galen 
who characterized the regression of larval and foetal structures in the course of 
ontogeny (Barclay et al., 1944). Several hundred years later, in the middle of the 19th 
century, Carl Vogt discovered during his investigations of the obstetrical toad that 
Introduction 
  
 6 
cells undergo programmed death (Vogt, 1842). Then, in the 20th century, inspired by 
the research of the embryologist Glücksmann on dying embryonic cells, Kerr, Wyllie 
and Currie first formulated the concept of “programmed cell death” and coined the 
term apoptosis (greek: apo - from, ptosis – falling) (Glücksmann, 1965; Kerr et al., 1972).  
Besides apoptosis, several other types of cell death are known. Necrosis, for instance, 
is a type of cell death that results from acute cellular injury and is accompanied by an 
inflammatory immune reaction and tissue destruction. Autophagy in contrast is a 
slow phenomenom characterized by the massive accumulation of cytoplasmic 
vacuoles (Galluzzi et al., 2007). In addition, also mixed forms of cell death exist. For 
example, although apoptosis and necrosis are different in their mode of action, there is 
evidence that both processes can be connected: the blockade of apoptotic signaling 
cascades can lead to necrotic cell death in certain scenarios (Vercammen et al., 1998).  
1.2.1 Apoptosis 
Together with cell proliferation, the mechanism of apoptosis provides the basis for the 
maintenance of tissue homeostasis in multicellular organisms. It plays a decisive role 
in development, proliferation and differentiation, e.g. during ontogeny, for the 
immune system and in the control of tumors (Krammer, 2000; Los et al., 1999; Vaux 
and Korsmeyer, 1999). It occurs when a cell is damaged beyond repair, virally infected 
or undergoing stress, such as starvation. 
Apoptosis is a strictly regulated cellular process, during which catabolic enzymes like 
proteases (e.g. cysteine-aspartic acid proteases (caspases), see below) and nucleases are 
activated. Cells undergoing apoptosis show characteristic morphological and 
biochemical features: during early apoptosis, cell shrinkage can be observed and the 
cell membrane starts to build protuberances caused by a loss of membrane integrity (a 
process called zeiosis). In the course of the apoptotic process, the cell membrane loses 
its asymmetry and lipids of the inner membrane layer, e.g. phosphatidylserine, are 
exposed on the cell surface. In parallel, chromatin condenses in the periphery of the 
nucleus. In most forms of apoptosis the DNA is degraded by special endonucleases in 
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the condensed chromosomes. This DNA degradation can be visualized by gel 
electrophoresis as DNA ladder, which arises from internucleosomal cleavage into 
single or multiple nucleosomal units of 200 base pairs (Wyllie et al., 1980). In a final 
step, membrane bound vesicles, so-called apoptotic bodies, which contain fragments 
of nucleus, cytoplasm and mitochondria, are released from the dying cell. Within a 
short period of time, apoptotic bodies are recognized by phagocytic cells, are taken up 
and degraded. This prevents the release of cytoplasmic constituents which would 
otherwise lead to inflammatory reactions (Savill et al., 1993).  
1.2.2 CD95 and other death receptor family members 
The discovery of CD95 (APO-1/Fas) as target molecule for monoclonal antibodies 
which induced apoptosis in distinct cell lines led to the first description of an 
apoptosis-inducing cell surface molecule (Yonehara et al., 1989; Trauth et al., 1989; 
Itoh and Nagata, 1993; Oehm et al., 1992). The death receptor CD95 is a differentially 
glycosylated type I transmembrane protein with a molecular mass of 42 to 52 kDa 
which is expressed by most mammalian tissues (Leithauser et al., 1993; 
Watanabefukunaga et al., 1992b). CD95 belongs to the tumor necrosis factor/nerve 
growth factor (TNF/NGF) receptor superfamily, which is involved in the control of 
biological processes like differentiation, activation, proliferation and apoptosis (Fig. 
1.2.1) (Locksley et al., 2001).   
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Besides CD95, seven other death receptors have been described in the death receptor 
subfamily thus far: TNF receptor 1 (TNF-R1/CD120a), DR3 (APO-3), TNF-related 
apoptosis-inducing ligand receptor 1 (TRAIL-R1/DR4/APO-2), TRAIL-R2 (DR5), 
DR6, ectodysplasin A receptor (EDA-R) and nerve growth factor receptor (NGF-R) 
(Fig. 1.2.1) (Askenasy et al., 2005; Bodmer et al., 2002; Schulze-Osthoff et al., 1998). The 
death receptors possess 2-4 extracellular cysteine-rich motives, a transmembrane 
region and an intracellular death domain (DD) which is essential for the stimulation-
dependent induction of apoptosis (Itoh and Nagata, 1993; Tartaglia et al., 1993). In 
addition to the death receptors, four decoy receptors (DcR) have been found: DcR3, 
TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and Osteoprotegrin (OPG) (Fig. 1.2.1). They 
cannot induce apoptosis and therefore inhibit the activation of death receptors by 
competitive ligand binding (Sheridan et al., 1997). 
TNF-R1 CD95 
(Fas/APO-1)
DcR3 TRAIL-R1 -R2 -R3 -R4 OPG DR6 EDA-R NGF-RDR3 
TNF-
CD95 ligand
(FasL/APO-1L/CD178) TL1A TRAIL APP EDA1 NGF
Figure 1.2.1 │ Death receptors, decoy receptors and their ligands. 
Members of the subfamily of death receptors (highlighted by gray boxes) are characterized by 2-
4 cysteine rich domains (blue), a transmembrane domain (yellow) and a cytoplasmic DD (red). 
Decoy receptors do not have a DD and cannot transduce the apoptotic signal but compete for 
ligand binding. The ligands for the death (and decoy) receptors are transmembrane proteins 
which mediate apoptosis by binding to their specific receptor [adapted from (Lavrik et al., 2005; 
Nikolaev et al., 2009)]. 
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1.2.3 The death-inducing ligand CD95L 
The ligands of the death receptors, with the exception of NGF, also belong to the TNF 
superfamily. The physiological ligand of the death receptor CD95, CD95 ligand 
(CD95L/APO-1L/FasL/CD178), is a glycosylated type II transmembrane protein with 
a molecular mass of 40 kDa (Nagata, 1994). Unlike CD95 which is ubiquituously 
expressed, the expression of CD95L is restricted to activated T cells, B cells and NK 
cells, as well as to some immune privileged non-lymphoid organs like the anterior 
chamber of the eye (Griffith et al., 1995; Kabelitz et al., 1993; Newell and Desbarats, 
1999; Suda et al., 1993). Furthermore, the expression of CD95L was shown in different 
neoplastic cells (Hahne et al., 1996; Strand et al., 1996). Also non-lymphatic tumors can 
express CD95L by which they circumvent anti-tumor immune responses mounted by 
T cells (Green and Ware, 1997). CD95L is expressed in three different forms: (1) 
membrane-bound on the cell surface, (2) membrane-bound in intracellular 
microvesicles which are released into the extracellular space by different physiological 
stimuli, and (3) in a soluble form by matrix metalloprotease-mediated cleavage from 
the cell surface (Tanaka et al., 1998; Schulte et al., 2007; Mariani et al., 1995; Kayagaki 
et al., 1995; Albanese et al., 1998). Recently, it was shown that the metalloprotease a 
disintegrin and metalloprotease-10 (ADAM-10) plays a major role in the cleavage of 
CD95L (Schulte et al., 2007).  
The membrane-bound form of CD95L has a high efficiency in the induction of 
apoptosis in mouse and man, while the soluble from has reduced apoptotic potential 
in humans and does not show any apoptotic function in mice (Hohlbaum et al., 2000; 
Schneider et al., 1998; Tanaka et al., 1995; Reilly et al., 2009). Spontaneous aggregation 
or association with extracellular matrix proteins is supposed to mediate the pro-
apoptotic effect of soluble CD95L (sCD95L) while the ineffectiveness of sCD95L 
homotrimers to aggregate CD95 might result in the non-apoptotic effect (Aoki et al., 
2001; Chen and Wilson, 1998; Hohlbaum et al., 2000; Schneider et al., 1998; Suda et al., 
1993; Tanaka et al., 1995; Tanaka et al., 1996). In addition, a chemotactic function as 
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well as a function as TF of CD95L has been shown (Kirkin et al., 2007; Seino et al., 
1998; Ottonello et al., 1999) 
1.2.4 Induction of apoptosis 
Apoptosis can be triggered via two fundamentally different pathways, the extrinsic 
(receptor-mediated) and the intrinsic (mitochondria-dependent) signaling cascade  
(Nagata, 1997; Green and Reed, 1998; Green, 1998). Both pathways activate the 
effector caspase 3 that eventually activates death substrates like caspase-activated 
DNase (CAD) by cleavage of the inhibitor of CAD (iCAD). CAD cleaves DNA into the 
characteristical 200 base pair long DNA fragments. 
1.2.4.1 The extrinsic – receptor-mediated – pathway  
The extrinsic signaling pathway is initiated by the activation of a death receptor 
through binding of its extracellular ligand or agonistic antibodies (Fig. 1.2.2) (Trauth 
et al., 1989; Yonehara et al., 1989; Kischkel et al., 1995; Bodmer et al., 2002). This 
receptor-mediated induction of apoptosis plays a major role in development, 
differentiation and in the homeostasis of the immune system and constitutes a part of 
the effector function of cytotoxic lymphocytes (Krammer, 2000). Stimulation of CD95 
leads within seconds to the formation of a multiprotein complex, the death-inducing 
signaling complex (DISC). The CD95 DISC is composed of oligomerized (most 
probably trimerized) CD95 molecules, the adaptor molecule Fas-associated death 
domain-containing protein (FADD) and the two splice variants of the proform of 
caspase 8 and 8. Caspases are proteolytic enzymes that cleave substrates at the 
carboxyterminal end of aspartic acid via a cysteine in their active center (Cohen, 1997; 
Villa et al., 1997; Raff, 1998; Hengartner, 2000). The CD95 DISC can also contain 
isoforms of cellular FLICE inhibitory protein (cFLIP) that either fulfil pro- or anti-
apoptotic function (Yu and Shi, 2008). In addition, procaspase 2 and procaspase 10 can 
be present in the DISC (Sprick et al., 2002; Lavrik et al., 2006). Caspase 8 is activated 
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Figure 1.2.2 │ The extrinsic and intrinsic apoptosis pathway. Binding of CD95L to 
CD95 initiates the extrinsic apoptosis pathway. CD95, FADD and caspase 8 form the DISC at 
which procaspase 8 is activated. Caspase 8 then activates caspase 3 by cleavage, eventually 
resulting in apoptosis. The intrinsic pathway triggered by stress stimuli is initiated by activation of 
Bim. Bim inhibits Bcl-2/Bcl-xL which leads to the activation of Bak and Bax. These molecules 
trigger the release of cytochrome c from mitchondria which in turn is recruited into the 
apoptosome. Caspase 9 is activated in the apoptosome and finally activates caspase 3 and 
induces apoptosis. The generation of tBid (gray inset) by low caspase 8 activity in type II cells 
triggers the intrinsic pathway for the propagation of the apoptotic signal [adapted from (Bouillet 
and O'Reilly, 2009)]. 
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in this multiprotein complex in an autoproteolytic fashion which triggers a caspase 
cascade in the cytosol (Lavrik et al., 2003). These events result in the cleavage of 
cellular substrates and initiate cell death (Fig. 1.2.2) (Krammer, 2000; Peter and 
Krammer, 2003; Yang et al., 1998). 
The CD95 signal transduction differs between cell types. Based on the amount of DISC 
formation, cells can be divided into type I and type II (Scaffidi et al., 1998; Scaffidi et 
al., 1999). Due to strong DISC activity, processed caspase 8 in type I cells can directly 
activate effector caspases like caspase 3 to trigger the execution of apoptosis (Scaffidi 
et al., 1999). Type II cells have less DISC activity resulting in low caspase 8 activation. 
In these cells, the CD95 DISC needs an amplification loop involving mitochondria for 
the induction of apoptosis (see below) (Scaffidi et al., 1998; Scaffidi et al., 1999).  
1.2.4.2 The intrinsic – mitochondria-dependent – pathway 
The intrinsic signaling pathway is activated by intra- or extracellular stimuli – like 
oxidative stress, irradiation, DNA damage or cytokine deprivation – resulting in the 
permeabilization of mitochondria and cell death (Ferri and Kroemer, 2001; Erlacher et 
al., 2005; Takahashi et al., 2004; Kroemer et al., 2007). Key molecules in the 
permeablization of mitochondria are pro- and anti-apoptotic proteins of the B cell 
lymphoma 2 (Bcl-2) family. Eponym of this family is the oncogene Bcl-2 which was 
originally identified in follicular B cell lymphoma as gene dysregulated by 
chromosomal translocation (Tsujimoto et al., 1985).  
Stress stimuli lead to the activation of p53-upregulated modulator of apoptosis 
(PUMA) or Bcl-2-interacting mediator of cell death (Bim) (Bouillet et al., 1999; Jeffers et 
al., 2003; Villunger et al., 2003). In contrast, in a potential cross-talk between the 
extrinsic and intrinsic pathway, BH3-interacting domain death agonist (Bid) is cleaved 
by the relatively low activity of caspase 8 in type II cells to its truncated form tBid (Fig. 
1.2.2) (Yin et al., 1999). Activated PUMA, Bim and tBid inactivate pro-survival Bcl-2 
family members like Bcl-2 and Bcl-xL. This liberates the pro-apoptotic family members 
Bcl-2-antagonist/killer (Bak) and Bcl-2-associated X protein (Bax) resulting in 
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disruption of the mitochondrial outer membrane potential and the formation of pores 
in the membrane (Gross et al., 1999; Chao and Korsmeyer, 1998; Green and Kroemer, 
2004; Kroemer et al., 1997; Petit et al., 1996). Here, cytochrome c is released from 
mitochondria into the cytosol where it binds to apoptotic protease-activating factor 1 
(Apaf-1) and ATP. Together with procaspase 9, these molecules create a protein 
complex known as apoptosome (Zou, 2006; Cain et al., 2000). Procaspase 9 is cleaved 
into its active form at the apoptosome which in turn results in cleavage and activation 
of the effector caspase 3 (Fig. 1.2.2). 
1.2.5 The role of CD95/CD95L in the immune system 
The discovery of several mutant mouse strains with defects in the CD95/CD95L 
system revealed the important role of CD95 in the immune system. The mouse strain 
lymphoproliferation (lpr) has a recessive autoimmune phenotype which arises 
through insertion of a transposon into the CD95 gene (Watanabefukunaga et al., 
1992a; Adachi et al., 1993; Rieux-Laucat et al., 2003). This results in decreased 
transcription and an almost complete lack of CD95 expression. The lprcg mutation, in 
contrast, is a point mutation in the DD of CD95 that abrogates signal transmission 
(Matsuzawa et al., 1990). A point mutation in the CD95L gene prevents the interaction 
of the ligand with its receptor CD95 in generalized lymphoproliferative disease (gld) 
mice (Roths et al., 1984). All three mouse strains develop lymphadenopathy, 
splenomegaly, hypergammaglobulinemia and nephritis among other autoimmune 
symptoms and display a characteristic accumulation of aberrant CD3+ B220+ CD4- 
CD8- T lymphocytes which might be derived from repeatedly activated T cells 
(Krammer, 2000; Nagata and Suda, 1995).  
In 1995, a mutation in the CD95 gene in a human patient linked the autoimmune 
lymphoproliferative syndrome (ALPS) with a dysregulation of the CD95/CD95L 
system (Rieuxlaucat et al., 1995; Fisher et al., 1995). Until now, mutations of CD95 
(ALPS type Ia), CD95L (type Ib) and caspase 10 (type II) which can result in ALPS 
have been described (Fisher et al., 1995; Rieuxlaucat et al., 1995; Jackson et al., 1999; 
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Lenardo et al., 1999; Straus et al., 2001; Del Rey et al., 2006; Wang et al., 1999). Yet 
unknown reasons are responsible for ALPS type III (Ten Bosch et al., 2001). Children 
suffering from ALPS show lymphadenopathy, elevated numbers of aberrant T cells 
and autoimmunity which resolves with age. 
1.2.6 CD95/CD95L-induced apoptosis in peripheral T cells 
The complex functions of the immune system regulate survival and death of T cells by 
finely tuned processes. Ag-specific T cells expand during an acute immune response 
and are removed after clearance of the pathogen except for a few cells which will give 
rise to Ag-specific memory T cells (Straus et al., 2001). The phenotype of lpr and gld 
mice points to a major role for the CD95/CD95L system and indeed CD95-mediated 
apoptosis represents an important mechanism in the regulation of T cell homeostasis, 
tolerance to self-Ag and autoimmunity (Askenasy et al., 2005).  
Depending on their activation status, T cells display resistance or sensitivity towards 
CD95-mediated apoptosis. Naïve and resting T cells are resistant to CD95-induced 
apoptosis, despite small amounts of CD95 expression (Klas et al., 1993; Krueger et al., 
2003b). After stimulation with Ag, naïve T cells acquire effector functions by clonal 
expansion, enhance the expression of CD95 but remain apoptosis resistant (Inaba et 
al., 1999). This resistance of activated T cells in the early stimulatory phase is caused 
by reduced DISC formation and a high expression of Bcl-xL. Repeatedly activated T 
cells become sensitive towards apoptosis by TCR re-stimulation-induced CD95L 
expression. Here, CD95L triggers AICD by binding to CD95 on the surface of the cell 
itself (suicide) and on neighbouring cells (fratricide) (Dhein et al., 1995; Ju et al., 1995; 
Klas et al., 1993; Singer and Abbas, 1994; Alderson et al., 1995; Brunner et al., 1995). 
Memory T cells in contrast are protected from CD95-mediated apoptosis by the 
elevated expression of cFLIP and the anti-apoptotic molecules Bcl-2 and Bcl-xL 
(Krueger et al., 2003b).  
Initial studies in mice pointed to a scenario in which the pool size of activated T cell 
clones during immune responses is controlled and regulated by the CD95/CD95L 
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system. However, the induction of CD95L on T cells undergoing AICD requires TCR 
re-stimulation with Ag that is not present in vivo after the decay of the immune 
response, as the pathogen has been cleared. The crucial parameter for T cell apoptosis 
is the decline of survival signals like cytokines (e.g. IL-2) and growth factors which 
results in activated T cell autonomous death (ACAD) (Straus et al., 1999; Brenner et 
al., 2008; Strasser et al., 2009). It was shown that Bim plays a major role in ACAD by 
the activation of the intrinsic apoptosis pathway (Erlacher et al., 2005; Hildeman et al., 
2002a; Sandalova et al., 2004; Willis et al., 2007). While Bim is essential for the deletion 
of T cells by ACAD in vivo after stimulation with super-Ag or challenge with Herpes 
Simplex Virus, CD95 is dispensable (Hildeman et al., 2002b; Strasser and O'Connor, 
1998; Pellegrini et al., 2003). However, during chronic immune responses where 
pathogenic Ag persists to stimulate already activated T cells repeatedly, it was 
demonstrated that killing of activated T cells requires not only Bim but also 
CD95/CD95L (Hughes et al., 2008; Hutcheson et al., 2008; Strasser, 1995; Weant et al., 
2008).  
1.2.7 In vitro cell death model for T cells 
For the investigation of CD95-induced apoptosis, an in vitro model for experiments 
with T cells has been established. Freshly isolated naïve (day 0) T cells are 
characterized by their resistance to apoptosis. They have low expression of CD95 and 
stimulation with a CD95L construct or plate-bound (pb) anti-CD3 monoclonal 
antibody (mAb) that activates the TCR does neither induce apoptosis nor AICD, 
respectively (Fig. 1.2.3). By expansion of day 0 T cells with anti-CD3 and anti-CD28 
mAb in IL-2 containing medium for 6 days, these cells are converted into apoptosis-
sensitive day 6 T cells. During culture, they upregulate the expression of CD95 and 
upon TCR re-stimulation, e.g. by pb anti-CD3 mAb they express high amounts of 
CD95L. Apoptosis induced by binding of endogenous CD95L to CD95 on day 6 T cells 
is referred to as AICD while stimulation with an artificial CD95L construct leads to 
CD95-induced apoptosis (Fig. 1.2.3) (Klas et al., 1993; Schmitz et al., 2003).  
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Figure 1.2.3 │ Cell death model used for in vitro experiments with T cells. Day 
0 T cells stimulated with a CD95L construct or pb anti-CD3 mAb do not become apoptotic. The 
expansion of day 0 T cells with anti-CD3/CD28 mAb and IL-2 results in apoptosis-sensitive day 6 
T cells. Direct CD95 stimulation (with the CD95L construct) or TCR re-stimulation (with pb anti-
CD3 mAb) induces apoptosis or AICD, respectively [adapted from (Strasser and Pellegrini, 
2004)]. 
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1.3  Regulatory T cells 
In 1970, Gershon and Kondo reported tolerance induction to a particular Ag in mice 
when thymic cells were present during Ag encounter and challenge, while their 
presence only during challenge resulted in immunity (Gershon and Kondo, 1970). 
Thus, a thymus-derived cell subset seemed to mediate immune tolerance through the 
suppression of other cells. In 1971, two individual reports by Gershon and Droege 
attracted more attention to this newly defined population of suppressor T cells 
(Gershon and Kondo, 1971; Droege, 1971). Subsequent studies showed that mice, 
thymectomized 2-4 days after birth, displayed T cell-mediated lesions which could be 
alleviated by the transfer of thymocytes or splenocytes (Sakaguchi et al., 1982b; 
Sakaguchi et al., 1982a). This pointed to a population of cells generated in the mouse 
thymus between day 2 and 4 capable of mediating immune tolerance in a dominant, 
cell-extrinsic manner. However, due to skepticism caused by the lack of specific 
molecular markers and difficulties in isolation and culture, research on suppressor T 
cells was discontinued (Moller, 1988; Janeway, 1988).  
Several years later, one major finding initiated the comeback of suppressor T cells. 
Sakaguchi and colleagues discovered that the interleukin-2 (IL-2) receptor  chain, 
CD25, could serve as a phenotypic marker for suppressive CD4+ T cells. Transfer of 
CD25-depleted CD4+ T cells into congenic nude mice resulted in autoimmune disease 
while transfer of total CD4+ T cells did not (Sakaguchi et al., 1995a). A similar 
population of suppressor cells was also found in humans and this CD4+CD25+ T cell 
subset was named Treg (Taams et al., 2001a; Dieckmann et al., 2001; Jonuleit et al., 
2001; Levings et al., 2001; Baecher-Allan et al., 2001).  
In 2001, another important finding added to the field. Autoimmune Scurfy mice and 
patients suffering from immune dysregulation, polyendocrinopathy, enteropathy X-
linked (IPEX) syndrome were found to have mutations in the gene of forkhead box P3 
(Foxp3) (Wildin et al., 2001; Brunkow et al., 2001; Bennett et al., 2001). This TF was 
reported as the master transcriptional regulator for naturally occurring Treg (nTreg).  
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1.3.1 Development and homeostasis of Treg 
Day 3-thymectomy and deletion of CD25-expressing cells in CD4+ SP thymocytes 
induces autoimmunity in mice caused by the absence of peripheral Treg (Sakaguchi et 
al., 1995b; Sakaguchi et al., 1996). This proved that Treg develop in the thymus in a 
delayed fashion compared to CD4+CD25- Tcon. 
Thymic Treg differentiation (defined by  Foxp3 induction) requires temporally and 
spatially separated signals (Fig. 1.3.1) (Josefowicz and Rudensky, 2009). 
(1) Strong TCR stimulation by a high binding affinity to self-Ag/MHC on TEC or DC 
is needed for thymic Treg differentiation (Jordan et al., 2001; Hsieh et al., 2004; 
Apostolou et al., 2002). One example are recombinase activating gene 2 (RAG2)+/+ 
TCR-transgenic (tg) mice in which Treg develop dependent on endogenous TCR 
rearrangement not using the tg TCR (Olivares-Villagomez et al., 1998). In RAG2-/- 
TCR-tg animals in contrast, Treg are generated only when the mice co-express the 
cognate ligand (Kawahata et al., 2002; Jordan et al., 2001).  
(2) CD28 signaling triggered by CD80 and CD86 expressed on APC is indispensable 
for Treg development. A marked decrease in Treg frequencies is observed in CD28-
deficient and CD80/CD86-deficient mice (Salomon et al., 2000; Tai et al., 2005).  
(3) Common  chain (c) signaling (mostly IL-2) is crucial for Treg differentiation. Mice 
lacking IL-2, IL-7 and IL-15 or c are almost completely devoid of Treg (Vang et al., 
2008; Malek, 2008; Burchill et al., 2007). All together, the strong TCR signal results in 
the upregulation of CD25, raising the responsiveness of Treg precursor cells to IL-2 
signals that result in the induction of Foxp3 (Burchill et al., 2007; Lio and Hsieh, 2008).  
In the periphery, the factors controlling the homeostasis of Treg are largely unknown, 
certain is the dependence of Treg on IL-2 produced by effector T cells (Teff), TGF- 
and CD28 costimulation (Fig. 1.3.1) (Malek, 2008).  
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Figure 1.3.1 │ Signals required for the development and maintenance of Treg. 
The process of Foxp3+ Treg differentiation from Foxp3- CD4+ thymocytes requires (1) strong TCR 
stimulation by self-Ag/MHC, (2) CD28 signaling triggered by CD80/86 on TEC or DC and (3) IL-2 
and other c cytokine receptor signaling. In the periphery, Treg homeostasis is mainly dependent 
on IL-2 produced by Teff [adapted from (Josefowicz and Rudensky, 2009)]. 
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1.3.2 Treg lineages 
In the periphery, maintenance of tolerance and prevention of autoimmunity is not 
only mediated by thymus-derived nTreg but also by various populations of induced 
Treg (iTreg) (Josefowicz and Rudensky, 2009; de Lafaille and Lafaille, 2009). iTreg can 
be experimentally induced or can be converted from T cells during inflammatory 
processes in peripheral tissues (de Lafaille and Lafaille, 2009). Different subsets of 
iTreg exist which can be divided into Foxp3+ adaptive Treg (aTreg) and Foxp3- T 
regulatory 1 (Tr1) cells as well as Foxp3- T helper 3 (Th3) cells which all display 
suppressive capacities.  
Suboptimal TCR stimulation or withdrawal of TCR signaling after short stimulation 
periods appear to be required for the generation of suppressive aTreg (Apostolou and 
von Boehmer, 2004; Sauer et al., 2008). Murine as well as human T cells can be 
converted into regulatory cells in the presence of TGF- and IL-2 (Yamagiwa et al., 
2001; Kretschmer et al., 2005; Chen et al., 2003).  
Foxp3- suppressive Tr1 cells can be converted from naïve T cells in the presence of Ag 
and high amounts of IL-10 and are themselves extensive producers of IL-10 and TGF-
 but produce only minimal amounts of IFN- and IL-5 (Shevach, 2006). The Ag-
specific suppression exerted by Tr1 cells seems to be mediated by IL-10 in vitro as well 
as in vivo (O'Garra and Vieira, 2004). Ag-specific Foxp3- Th3 cells can be induced in 
the context of oral tolerance by Ag feeding in vivo (Weiner, 2001). In vitro generation of 
these cells is achieved by the addition of TGF-, IL-4,  IL-10  and  anti-IL-12 mAb to 
the culture medium. Th3 cells release significant amounts of TGF- and small 
amounts of IL-4 and IL-10 and can suppress Ag-specific Teff. Immunosuppressive 
drugs as well as immature DC can also be used for the generation of suppressive 
Foxp3- Tr1 or Th3 cells (Barrat et al., 2002; Jonuleit et al., 2000; Weiner, 2001). In vivo, 
Foxp3- suppressive cell types are mainly found in the intestine (Weiner, 2001).  
However, thus far it is neither known to which extent iTreg contribute to peripheral 
tolerance nor which percentage of the peripheral Treg pool they comprise (Chen et al., 
2003). 
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1.3.3 Characteristics of Treg  
Thymus-derived nTreg comprise 1-3% of the CD4+ T cell population in humans and 5-
10% in mice. There is no surface marker that uniquely identifies human and murine 
Treg, but Treg express a distinct set of cell surface proteins compared to non-
stimulated Tcon. Constitutive expression of CD25 is restricted to Treg in non-
immunized mice while in humans, only cells that highly express CD25 designate Treg 
whereas activated Tcon acquire intermediate levels of CD25 (Sakaguchi et al., 1995b; 
Baecher-Allan et al., 2001). Together with CD25, cytotoxic T lymphocyte antigen-4 
(CTLA-4) and glucocorticoid-induced TNF receptor (GITR) have been candidates for 
Treg markers as they both play a major role in the development of suppressive 
properties (Mchugh et al., 2002; Read et al., 2000; Shimizu et al., 2002). However, due 
to the fact that also activated Tcon upregulate CTLA-4 and GITR these are no longer 
regarded as sufficient for the explicit identification of Treg. Of the numerous other 
markers that have been reported to be on the surface of Treg, two recently discussed 
molecules should be mentioned. One is CD127, the  chain of the IL-7 receptor, and 
the other CD49d, the integrin 4 chain. CD127 is expressed by almost all CD4+ T cells 
except most CD25+ Treg while CD49d is present on activated T cells but not on Treg 
(Seddiki et al., 2006a; Liu et al., 2006; Kleinewietfeld et al., 2009; Hartigan-O'Connor et 
al., 2007).  
1.3.4 Foxp3 – a Treg-specific transcription factor  
At present, the most specific marker for the characterization of Treg is the TF Foxp3 
whose discovery was achieved by the investigation of the scurfy mouse and human 
IPEX patients. The X chromosome-encoded Foxp3 gene belongs to the winged/helix 
family of TF whose members are crucial in development, metabolism, cancer and 
aging, and important in the immune system (Brunkow et al., 2001; Ziegler, 2006). Male 
scurfy mice harbor a mutation in Foxp3 which leads to severe autoimmune disease 
and causes death within 3-4 weeks after birth. A detailed analysis of lymphocyte 
populations showed that the animals suffer from hyperproliferative CD4+ T cells 
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and from a lack of CD4+CD25+ Treg (Hori et al., 2003; Fontenot et al., 2003; Ziegler, 
2006). Amelioration of the symptoms could be achieved by adoptive transfer of 
CD4+CD25+ T cells from wild type (wt) animals. Similar to scurfy mice, hemizygous 
male IPEX patients display massive inflammatory processes. The disease is treated 
with strong immunosuppressive drugs or even BM transplantation (Bennett et al., 
2001; Wildin et al., 2001). Until now, 20 mutations in the Foxp3 gene were found to be 
responsible for the IPEX syndrome (Bacchetta et al., 2006). 
In wt mice, up to 90% of Treg express Foxp3, while resting and activated naïve CD4+ T 
cells do not show detectable levels. Analogous to mice, also the majority of ex vivo 
sorted human CD4+CD25++ Treg express Foxp3. However, while Foxp3 cannot be 
detected in mouse Tcon, human activated CD4+ non-Treg transiently express 
intermediate levels of Foxp3 which can go along with suppressive function  (Wang et 
al., 2007; Walker et al., 2003; Gavin et al., 2006).  
The investigation of Foxp3-deficient Treg showed that although these cells lose their 
suppressive capacity in vitro and in vivo and can produce Teff cytokines, they largely 
retain their genetic signature and do not induce autoimmunity upon transfer into 
lymphopenic hosts (Gavin et al., 2007; Lin et al., 2007; Lahl et al., 2009; Kuczma et al., 
2009). Interestingly, negative selection of thymocytes by a high-affinity TCR ligand is 
not affected by the presence or absence of Foxp3 (Hsieh et al., 2006; Chen et al., 2005). 
In addition, activated T cells in Foxp3-deficient mice use TCR sequences similar to 
Foxp3-sufficient Treg (Hsieh et al., 2006; Chen et al., 2005). These two findings 
indicate that T cell precursors supporting Treg differentiation are not deleted in the 
absence of Foxp3. Together with data showing that Foxp3-negative Treg numbers 
gradually decrease in Foxp3+/- female mice (while Foxp3-sufficient Treg numbers do 
not), these results imply that Foxp3 is dispensable for the development of Treg but 
essential for function, proliferation and survival (Lin et al., 2007; Gavin et al., 2007). 
Indeed, the necessity of the TF Foxp3 for suppressive capacities was demonstrated in 
several murine studies. Foxp3 knock-out mice develop an autoimmune-like 
lymphoproliferative syndrome with hyperreactive CD4+ T cells and the deletion of 
Foxp3+ T cells leads to an autoimmune disease like in scurfy mice (Lahl et al., 2007; 
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Kim et al., 2007; Fontenot et al., 2003). Furthermore, retroviral transduction of naïve T 
cells with the Foxp3 gene results in anergy, an expression profile of nTreg, and in 
some publications in suppressive capacity against CD4+ T cells (Hori et al., 2003; 
Fontenot et al., 2003; Allan et al., 2005). 
Association of Foxp3 with other TF, such as nuclear factor of activated T cells (NFAT), 
NF-κB and runt-related TF 1/acute myeloid leukaemia 1 (RUNX1/AML1) is required 
for its gene regulatory function (Bettelli et al., 2005; Ono et al., 2007; Wu et al., 2006). 
Foxp3 together with NFAT enhances CD25 and CTLA-4 transcription (Fig. 1.3.2) 
(Sakaguchi, 2005). In contrast, IL-2 expression which is increased by NFAT alone is 
repressed when this TF is complexed with Foxp3 (Fig.1.3.2) (Wu et al., 2006).  
In the course of particular immune responses, Treg can express TF specific for the 
predominantly active T cell subset. For instance, simultaneous expression of Foxp3 
and T-bet (a Th1-specific TF), interferon regulatory factor 4 (IRF4, Th2-specific) or 
signal transducer and activator of transcription 3 (STAT3, Th17-specific) adapts Treg 
to the specific environment and leads to the suppression of the corresponding T cell 
subsets (Chaudhry et al., 2009; Zheng et al., 2009; Koch et al., 2009). In the case of 
Figure 1.3.2 │Foxp3-mediated transcriptional control in Treg. Foxp3 positively 
regulates some genes encoding Treg-associated molecules (e.g. CD25, CTLA-4 and GITR) while it 
suppresses the transcription of others (e.g. effector cytokines such as IL-2 and IL-4) [adapted 
from (Sakaguchi, 2005)]. 
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NFAT, IRF4 and retinoid related orphan receptor (ROR)t, a direct interaction with 
Foxp3 has been reported. This interaction might induce effector cell-specific 
suppression conditions in Treg by modified gene transcription (Wu et al., 2006; Zheng 
et al., 2009; Du et al., 2008). One presumable scenario is a Treg-specific expression of 
receptors that catch lineage defining factors from the immune response-driving T cell 
subsets.  
Thus far, although Foxp3 is the most specific marker for Treg it remains unsuitable for 
the isolation of functional Treg due to its intracellular location. Hence, the discovery 
of a specific cell surface marker for the isolation of Treg remains a major challenge. 
1.3.5 Suppression mechanisms of Treg 
Recent studies have acknowledged Treg to be instrumental in the maintenance of 
tolerance, the prevention of autoimmune diseases, such as type 1 diabetes (Sakaguchi 
et al., 2001), and the limitation of chronic inflammatory diseases, such as 
inflammatory bowel disease (Xystrakis et al., 2006). Treg can suppress different 
effector functions of CD4+ and CD8+ T cells, B cells, NK cells and the function and 
maturation of DC (Piccirillo and Shevach, 2001; Thornton and Shevach, 1998; Lim et 
al., 2005; Ghiringhelli et al., 2005; Misra et al., 2004; Tadokoro et al., 2006). The 
tolerance exerted by Treg can be classified as dominant as the mere presence of Treg 
can inhibit autoimmunity.  
Numerous mechanisms are used by Treg to suppress immune responses, e.g. direct 
cell-cell contact, the production of anti-inflammatory cytokines, and by modulating 
the activation state and function of APC. Another potential mechanism by which Treg 
mediate suppression is via the induction of apoptosis (this will be further discussed in 
paragraph 1.3.7.1). Below, some important mechanisms of suppression will be 
discussed briefly.  
The role of TGF- remains controversial in vivo whereas it does not play a role in most 
in vitro suppression assays. TGF--deficient Treg are suppressive, but TGF- derived 
from non-Treg sources seems to be required for the protection from inflammatory 
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bowel disease (Fahlen et al., 2005; Mamura et al., 2004). In addition, the secretion of 
IL-10 by Treg in vivo has been shown in multiple studies to constitute an important 
component of their suppressive effects (Belkaid, 2007; McGeachy et al., 2005). 
CTLA-4 sufficient Treg condition DC to express indoleamine 2,3-dioxygenase (IDO) 
which catalyzes tryptophane into proapoptotic metabolites resulting in the 
suppression of Tcon activation (Oderup et al., 2006; Valzasina et al., 2005; Fallarino et 
al., 2003) Hydrolysis of extracellular ATP (an indicator of tissue destruction with 
inflammatory effects on DC) to ADP or AMP by the ectoenzyme CD39 expressed by 
all murine Treg and about 50% of human Treg represents another anti-inflammatory 
Treg-mediated mechanism. Adenosine generated by CD39 in concert with the 5’-ecto-
nucleoside CD73 signals via the A2A adenosine receptor and may inhibit the function 
of DC as well as act directly on activated T cells (Borsellino et al., 2007; Deaglio et al., 
2007; Kobie et al., 2006). Also cAMP, which rises in CD4+ T cells upon co-culture with 
Treg, contributes to a decrease in IL-2 production and lack of proliferation in CD4+ T 
cells (Bopp et al., 2007).  
It is not clear how and if different mechanisms are connected with each other to obtain 
maximal suppressive activity. The existence of multiple subpopulations of Treg leads 
to the hypothesis that depending on the tissue and type of immune reaction, different 
suppression mechanisms are important. 
1.3.6 Treg in diseases 
The relevance of Treg in cancer, autoimmune diseases, transplantation and virus 
infections has been demonstrated in clinical studies and in in vitro experiments (Curiel 
et al., 2004; Petersen et al., 2006; Kinter et al., 2007; Sakaguchi et al., 2006). The TCR 
repertoire of Treg is skewed towards recognizing self-Ag/MHC and Treg stimulation 
by their respective Ag results in the suppression of autoimmunity, hampered tumor 
immunity and dampened graft rejection. In that context, a diminished number of 
functional or normal numbers of non-functional Treg have been correlated with 
different autoimmune diseases (Abdulahad et al., 2007; Banica et al., 2009; Okumura 
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et al., 2008). In contrast, an increase of Treg can lower anti-tumor responses via 
suppression of tumor-specific effector T-cell responses (Wang and Wang, 2007). It was 
shown that Treg empede immunosurveillance against autologous tumor cells, because 
depletion of Treg before tumor challenge elicits effective immune responses to 
syngeneic tumors (Sutmuller et al., 2001; Onizuka et al., 1999). Furthermore, depletion 
of Treg and subsequent stimulation with Ag in vitro results in the expansion of tumor 
Ag-reactive T cell populations (Danke et al., 2004). Currently, different methods with 
beneficial outcome are being used for the manipulation of Treg in the clinic. 
Denileukin diftitox, for instance, a fusion protein of diphtheria toxin (DT) and IL-2 
which targets CD25-expressing cells for lysis, can reduce the percentage of Treg in 
patients with ovarian cancer, renal carcinoma, and melanoma (Dannull et al., 2005; 
Rasku et al., 2008; Morse et al., 2008; Mahnke et al., 2007a; Barnett et al., 2005). 
Furthermore, the humanized mAb Daclizumab which binds specifically to CD25 has 
been given to organ transplantation patients, patients with autoimmune disorders, 
and cancer patients with CD25+ T-cell malignancies or acute GvHD (Waldmann, 2007) 
1.3.7 Treg and apoptosis 
Numerous articles have been published about Treg in conjunction with apoptosis 
which are, however, controversial. Several laboratories show that Treg exert 
suppression by apoptosis while others demonstrate that Treg are killed by their target 
cells often involving the same molecules in both mechanisms. Discrepancies might 
arise from varying experimental setups and differences between the murine and 
human system. The most relevant data regarding apoptosis will be discussed briefly 
in the following two paragraphs. 
1.3.7.1 Apoptosis-mediated suppression and counter-suppression 
Regarding apoptosis induction in responder cells, a study proposed that murine Treg 
consume IL-2 and inhibit the proliferation of Tcon by Bim-dependent apoptosis 
(Pandiyan et al., 2007). In contrast, blockade of IL-2 binding to CD25 had no effect 
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on suppression of proliferation and the addition of exogenous IL-2 did not affect the 
suppression of IL-2 mRNA production (Tran et al., 2009; Oberle et al., 2007; Thornton 
et al., 2004). Furthermore, Noelle and colleagues were the first to describe that the 
suppressive capacity of murine Treg depends on  granzyme B (GzmB), but is perforin-
independent and that GzmB-deficient Treg have reduced suppressive activity in vitro 
(Cao et al., 2007; Gondek et al., 2005). In humans, Treg express GzmA and kill 
different cell types in a perforin-dependent manner (Grossman et al., 2004). Other 
studies demonstrated that a fraction of tumor-infiltrating Treg lysed NK cells and 
cytolytic T cells in a perforin-dependent manner (Cao et al., 2007). In addition, it has 
been shown that Treg can mediate lysis of B cells (Zhao et al., 2006; Janssens et al., 
2003; Ludwig-Portugall et al., 2009). Furthermore, activated Treg could kill previously 
activated Tcon in a TRAIL-dependent and CD95-independent fashion in vivo (Ren et 
al., 2007; Baatar et al., 2007). In contrast to that, it was demonstrated in an in vitro 
model that Treg could induce apoptosis in Jurkat cells via CD95 (Baatar et al., 2007).  
The killing of Treg by effector cells to circumvent suppression has also been 
investigated by several laboratories. For CD95-induced apoptosis, Reardon et al. 
demonstrated in a colitis model that Treg numbers decrease due to the presence of 
CD95L+ cells (Reardon et al., 2008). In addition, tumor cells engineered to present 
CD95L were able to diminish Treg numbers in a murine tumor model (Chen et al., 
2007). Furthermore, GzmB+ responder cells could kill a subset of human Treg in vitro 
(Ashley and Baecher-Allan, 2009).  
1.3.7.2 Treg are sensitive to CD95-induced apoptosis but lack AICD 
Previous studies demonstrated that Treg behave differently from Tcon regarding 
apoptosis (Fritzsching et al., 2005; Taams et al., 2001b; Taylor et al., 2007; Banz et al., 
2002). As described in paragraph 1.2.4, freshly isolated (day 0) Tcon express very low 
levels of CD95 and are resistant to apoptosis mediated by a CD95L construct as well 
as TCR stimulation-induced AICD (Fig. 1.3.3, day 0 Tcon). Tcon upregulate CD95 and 
become sensitive to apoptosis during an in vitro culture of 6 days with anti-
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CD3/CD28 mAb and IL-2. Stimulation of day 6 Tcon with a CD95L construct leads to 
CD95-induced cell death, while TCR re-stimulation with pb anti-CD3 mAb results in 
AICD (Fig. 1.3.3, day 6 Tcon).  
Day 0 and day 6 Treg express CD95 and behave similar regarding apoptosis 
sensitivity in vitro. They can easily be killed via cross-linking of CD95 by a CD95L 
construct, but they are resistant to AICD triggered by TCR re-stimulation (Fig. 1.3.3, 
day 0/day 6 Treg) (Taylor et al., 2007; Fritzsching et al., 2005). As the CD95-mediated 
death pathway is functional, the lack of Treg regarding AICD might be caused by 
inadequate CD95L levels (Fig. 1.3.3, day 0/day 6 Treg). It has been shown that gld 
mice which lack functional CD95L have increased Treg numbers whereas lpr mice 
were not reported to have altered Treg numbers (Mohamood et al., 2006; Zheng et al., 
2007a). Therefore, a detailed analysis to elucidate the role of the CD95/CD95L system 
in the homeostasis of Treg is required.  
activation-induced cell death
day 6 Tcon
CD95-induced cell death
CD95LCD95
day 0/day 6 Treg
activation-induced cell deathCD95-induced cell death
?
day 0 Tcon
no cell death
CD95L 
construct
anti-CD3
mAb
TCR
+ or
Figure 1.3.3 │Apoptosis pheno-
type of Tcon and Treg on day 0 
and day 6. Day 0 Tcon are resistant to 
apoptosis induced by a CD95L construct 
and by TCR stimulation (anti-CD3 mAb). 
Expanded (day 6) Tcon express high 
levels of CD95 and can be killed by direct 
CD95 stimulation as well as by TCR 
stimulation. Day 0/6 Treg can be killed 
by CD95 cross-linking, but are resistant 
to AICD, probably due to low CD95L 
expression.  
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1.4 Aim of the study 
Previous experiments have demonstrated that Treg are highly sensitive to CD95-
induced apoptosis but simultaneously resistant to AICD in vitro, the latter being 
characterized by production and subsequent binding of CD95L to CD95. Two 
questions arise from these results: Firstly, do Treg have low/absent CD95L expression 
which makes it impossible for them to undergo AICD? This question is to be 
answered by the investigation of CD95L expression by Treg upon stimulation. 
Secondly, Treg are sensitive to CD95-induced apoptosis in vitro but do they also 
display this apoptosis phenotype in situ where they should receive all factors required 
for their survival? The involvement of CD95 in the apoptosis of Treg will be 
investigated in vivo by means of a mouse model.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Laboratory materials 
Consumables  Company 
Reaction tubes (1.5, 2ml)  Eppendorf  
Reaction tubes (5, 15, 50ml)  Becton Dickinson  
Sterile filters (0.22μm, 0.45μm)  Millipore  
Cell culture plates TPP/Greiner 
Cell culture flasks TPP 
Pipettes  Becton Dickinson 
Pipette tips TipOne 
LS, LD, MS columns Miltenyi Biotec 
2.1.2 Equipment 
Device Company 
Analysis scale AE 240  Mettler  
Biofuge 15  Heraeus  
Biofuge Fresco 17 Heraeus  
Megafuge 3.OR  Heraeus  
Omnifuge 3.ORS  Heraeus  
Thermomixer compact  Eppendorf 
Heating block Thermostat 5320  Eppendorf  
Steril bench place HeraSafe Heraeus 
FACSCanto II   Becton Dickinson  
Thermocycler DNA engine Dyad  
7500 Real Time PCR systems Applied Biosystems 
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Nucleofector I Amaxa Biosystems 
IVIS 100 Imaging System Xenogen Imaging Technologies 
Magnetic stand Miltenyi Biotec 
2.1.3 Chemicals 
All chemicals, if not otherwise stated, were ordered from the companies Fluka, Merck, 
Roth, Serva and Sigma.  
2.1.4 Standard buffers 
Buffer  Reagents 
Hypotonic NaCl buffer (10x)  2% (w/v) NaCl in H2O  
PBS  137mM NaCl  
8.1mM Na2HPO4 
2.7 mM KCl  
1.5mM KH2PO4 
pH 7.4  
FACS buffer  5% FCS  
0.1% NaN3 
in PBS  
MACS buffer (human) 0.5% HSA  
2mM EDTA  
in PBS  
MACS buffer (murine) = FASER buffer 0.5% BSA  
2mM EDTA  
in PBS  
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2.1.5 Cell lines and primary cells 
The erythroleukemic cell line K562 and the thereof derived CD95L+ cell line KFL9 
were used for CD95L control stainings.  
Human and murine primary T cells were isolated from human buffy coats (Blutbank 
Karlsruhe) or blood donations and pooled murine lymph node (LN)/spleen cells, 
respectively (see paragraph 2.2.4).  
BM cells were isolated from femur and tibia of mice and depleted of CD3+ cells by 
MACS purification (see paragraph 2.2.6). 
2.1.6 Media and supplements  
Reagent  Company  
RPMI 1640 Sigma  
X-Vivo 15 Cambrex 
FCS Gibco 
Glutamax Gibco 
Penicillin/Streptomycin Sigma 
2.1.7 Reagents for the isolation/depletion of T cells 
Reagent  Company  
Ficoll Biochrom 
Anti-human CD25 beads 
CD4+ T cell isolation kit II, human 
CD4+CD25+ regulatory T  cell isolation kit, mouse 
CD4+ T cell isolation kit, mouse 
Anti-FITC beads 
Miltenyi Biotec 
FITC-coupled anti-mouse CD3 BD Pharmingen 
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2.1.8 Antibodies/reagents for the stimulation/expansion of T cells 
Antibody/reagent  Company  
Anti-human CD3 (OKT3) Cytonet  
Mouse IgG2a BD Pharmingen 
anti-human CD28  Provided by Gerd Moldenhauer, DKFZ 
Anti-mouse CD3 (2C11) BD Pharmingen 
Armenian Hamster IgG1 BD Pharmingen 
Anti-mouse CD28 BD Pharmingen 
Recombinant human IL-2 Cell line LBRM-33 5A4  
Phorbol 12-myristate 13-acetate (PMA) Sigma 
Ionomycin Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
ADAM-10 inhibitor Provided by Andreas Ludwig, 
University clinic Aachen 
2.1.8 Antibodies/reagents for flow cytometry 
Antibody/reagent  Company  
Biotinylated anti-human CD95L (NOK1) BD Pharmingen 
Biotinylated hamster IgG1 BD Pharmingen 
FITC-coupled anti-human CD45RO BD Pharmingen 
PE-coupled anti-human CD45RA BD Pharmingen 
PE-coupled anti-human Foxp3 (259D) Biolegend 
PE-coupled mouse IgG1 BD Pharmingen 
Foxp3 staining buffer set eBioscience 
Biotinylated anti-mouse CD95L (MFL3) BD Pharmingen 
Biotinylated armenian hamster IgG1 BD Pharmingen 
PE-coupled anti-mouse CD3 BD Pharmingen 
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PE-Cy5-coupled anti-mouse CD4 BD Pharmingen 
APC-coupled anti-mouse B220 (CD45R) eBioscience 
APC-coupled streptavidin  BD Pharmingen 
APC-specific FASER kit Miltenyi Biotec 
2.1.9 RNA isolation, reverse transcription and quantitative PCR reagents  
Reagent  Company  
Absolutely RNA Microprep kit  Stratagene  
Turbo DNA-free Kit  Ambion  
Reverse Transcriptase  Applied Biosystems  
RNase Inhibitor  Applied Biosystems  
Power SYBR green master mix  Applied Biosystems  
2.1.10 Primers 
Synthetic oligodesoxyribonukleotides were designed with the program “Primer 
Express” (Applied Biosystems) and ordered from MWG Biotech.  
Name Sequence (5’-3’) 
Primers (for the detection of human genes of interest) 
GAPDH 
Forward: GCA AAT TCC ATG GCA CCG T 
Reverse: TCG CCC CAC TTG ATT TTG G 
CD95L 
Forward: TGG AAT TGT CCT GCT TTC TGG 
Reverse: TGT TGC AAG ATT GAC CCC G 
2.1.11 siRNA reagents  
Reagent Sequence (5’-3’)/company 
siRNA against Foxp3 GCA CAT TCC CAG AGT TCC T/MWG 
AllStars Negative Control siRNA Qiagen 
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T cell nucleofection kit Amaxa/Lonza 
2.1.12 Antibodies/reagents for in vivo T cell experiments 
Name Company 
Anti-mouse CD95 (Jo2) BD Pharmingen 
Armenian hamster IgG21 BD Pharmingen 
Diphtheria toxin (DT) Sigma 
D-luciferin potassium salt Synchem OHG 
2.2 Methods 
2.2.1 Standard cell culture methods 
Cell culture was carried out at a sterile bench. Glass ware and self-made solutions 
were autoclaved (30 min, 121°C). Other solutions and plastic ware was ordered sterile. 
Cells were cultured at 37°C and 5% CO2.  
For the culture of K562 and KFL9 cells, RPMI 1640 medium was supplemented with 
10% FCS, 1% Glutamax and 1% Penicillin/Streptomycin. Medium was exchanged 
every 2-3 days.  
Primary murine T cells were cultured in RPMI 1640 supplemented as described for 
K562 and KFL9 cells. 200 IU/ml IL-2 were added freshly to the culture. 
For the culture of primary human T cells, X-Vivo 15 medium was supplemented with 
1% Glutamax. 200 IU/ml IL-2 were added freshly to the culture. 
2.2.2 Cell counting 
Cells were counted and viability was measured by staining with trypan blue. 10µl of 
cell suspension was mixed with 10µl 1x trypan blue and counted in a Neubauer 
chamber. The cell number/ml was calculated according to the following formula: 
Counted cell number/number of counted squares x dilution factor x 104.  
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2.2.3 Freezing and thawing of cell lines  
Cell lines were adjusted to 2 x 107/ml in RPMI containing 40% FCS and 10% DMSO 
and transferred into cryo tubes. Cells were frozen over night at -20°C and then stored 
at -80°C.  
Cells were thawed quickly at 37°C and washed immediately in 50ml RPMI containing 
10% FCS. The cells were resuspended in RPMI supplemented as explained in „Media 
and supplements“, transferred into a cell culture flask and cultured in an incubator.   
2.2.4 Ficoll gradient isolation of human mononuclear cells 
Primary human mononuclear cells were isolated from 500ml total blood or buffy coats 
according to the following protocol. Buffy coats were adjusted to 300ml with PBS. 
50ml tubes filled with 15ml Ficoll were slowly overlayed with 35ml blood and 
centrifuged at 650 x g and 20°C for 20 min without break. Peripheral blood leukocytes 
(PBL) were collected from the interphase and washed once with PBS and resuspended 
in RPMI containing 10% FCS. PBL were transferred into cell culture flasks and 
cultured for 30-45 min in the incubator for the depletion of adherent cells (monocytes 
and macrophages). Non-adhering lymphocytes were washed from the cell culture 
flask with medium and stored over night at 4°C. Lymphocytes were used for the 
further purification of CD4+CD25- Tcon and CD4+CD25+ Treg by magnetic sorting (see 
paragraph 2.2.6). 
2.2.5 Isolation of murine cells from organs (LN, spleen) 
Mice were killed by cervical dislocation and organs were isolated immediately. 
Inguinal, axillary, lateral axillary, mesenteric and sacral LN were pooled in RPMI 
containing 10% FCS on ice. In addition, the spleen was isolated and kept in 
RPMI/10% FCS on ice. Both organ types were grinded separately through a 0.45µm 
cell strainer to obtain single cell suspensions. Cells were pelleted by centrifugation; 
LN cells were resuspended in PBS and kept on ice, while splenocytes were depleted of 
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erythrocytes by resuspension in hypotonic NaCl solution for 30 seconds. Splenocytes 
were centrifuged again and resuspended in PBS. LN and spleen cells were pooled in 
some experiments for the isolation of either CD4+CD25- Tcon and CD4+CD25+ Treg or 
total CD4+ T cells by magnetic sorting (see below). In other experiments they were 
used separately. 
2.2.6 Magnetic-activated cell separation of Tcon, Treg and CD4+ T cells 
The isolation of T cells was accomplished by means of magnetic-activated cell 
separation (MACS). Cells can be separated by MACS either by positive or negative 
selection. Human CD25++ Treg were isolated by positive selection from PBL that had 
been isolated from buffy coats or total blood. For that, the cell suspension was 
incubated with a limiting amount (2µl/107 cells) of bead-coupled anti-CD25 mAb 
(Stassen et al., 2004). After a subsequent washing step, the cell suspension was loaded 
onto a column in a magnetic field. The magnetic beads retain the CD25+ cells in the 
column, while the remaining cell types flow through. Outside of the magnetic field, 
CD25+ cells were eluted from the column. The CD25+ cell fraction was run a second 
time over a column to obtain highly purified CD25++ Treg. After elution, the cells were 
stored in X-Vivo 15 until the start of experiments. The remaining cell suspension 
(partially depleted of CD25+ cells) was used for the isolation of CD4+CD25- Tcon with 
the CD4+ T cell isolation kit II and an additional amount of anti-CD25 beads. During 
the CD4-specific negative selection, other cell types (B cells, NK cells, CD8+ T cells, 
erythrocytes, residual CD25+ cells) except the cells of interest (CD4+CD25- Tcon) are 
bound by specific antibodies coupled to beads. Therefore, CD4+ Tcon flow through 
the column in the magnetic field. After the isolation they can be used for experiments.  
For the isolation of cord blood Tcon and Treg, PBL from cord blood donations were 
incubated with 3µl bead-coupled anti-CD25 mAb. After the positive selection which 
yields the CD25+ cell fraction (in cord blood exclusively Treg are CD25+), cells were 
subjected to a CD4-specific negative selection to obtain CD4+CD25- Tcon.  
Murine Tcon and Treg were isolated from organ suspension (pooled LN and spleen 
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cells) by means of the mouse CD4+CD25+ regulatory T cell isolation kit. In a first step 
CD4+ T cells are isolated by negative selection. Subsequently, CD25+ T cells are 
marked by beads and separated from the remaining CD4+ T cells to yield CD4+CD25- 
Tcon and CD4+CD25+ Treg.  
For some experiments, total murine CD4+ T cells were isolated by MACS. For that, 
pooled LN and spleen cells were incubated with biotinylated mAb that labels all cell 
types except CD4+ T cells. In a subsequent step, the cell mixture was incubated with 
streptavidin-coupled beads. The cell suspension was run through a column resulting 
in non-labeled CD4+ T cells in the flow through which are used for further 
experiments. 
2.2.7 Expansion of T cells by anti-CD3 and anti-CD28 mAb 
0.5-1 x 104 T cells were resuspended in 200µl supplemented X-Vivo 15 medium and 
transferred into individual wells of 96-u-well plates. Soluble anti-CD3 (0.5µg/ml) and 
anti-CD28 (2µg/ml) mAb as well as 200-300 IU/ml IL-2 was added to the medium. T 
cells were used after different in vitro culture periods (day 1-6).  
2.2.8 Stimulation of T cells 
For the investigation of CD95L expression, human and murine T cells were stimulated 
with 30µg/ml pb anti-human CD3 mAb (OKT3) and pb 3µg/ml anti-mouse CD3 mAb 
(2C11), respectively. As a control, T cells were incubated with specific pb isotype 
mAb. In addition, T cells were incubated with the strong stimulus PMA (10ng/ml) 
plus Ionomycin (1µM) or the vehicle control DMSO. For the investigation of CD95L 
mRNA, cells were stimulated for 2 hr, while CD95L protein expression was 
investigated after 20 hr of stimulation. In some experiments for the investigation of 
CD95L protein, cells were incubated during stimulation with 1µM of the hydroxamate 
based ADAM-10 inhibitor GI254023X (Hundhausen et al., 2003). 
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2.2.9 RNA isolation 
RNA was isolated according to the manual of the absolutely RNA Microkit. Briefly, 1-6 x 105 
cells were lysed in 200 μl lysis buffer supplemented with -mercaptoethanol and either stored 
at –20°C or immediately adjusted to 400µl with 200µl 70% ethanol. The purification was 
achieved via binding to a column. Columns were washed twice with 500µl high salt buffer and 
3 times with 300µl low salt buffer. The RNA was eluted with 20-40µl DEPC water (60°C) and 
subjected to a DNase treatment with the turbo DNA-free Kit according to the manufacturer’s 
guidelines.  
2.2.10 Reverse Transcription 
RNA was reverse transcribed into complementary DNA by the use of oligo dT 
primers (5µM). In a 10 min step at 65°C, the RNA was stretched to allow easier 
attachment of the oligo dT primers. Afterwards, RNA was incubated for 45 min at 
42°C in a reaction mix containing: 
1x reaction buffer 
5 mM MgCl2 
1 mM dNTP 
0.5 U/μl Reverse Transcriptase 
1 U/μl RNAse Inhibitor 
In a final step, the reaction was stopped by incubation at 95°C for 5 min 
2.2.11 SYBR green quantitative real time PCR 
Expression of the gene of interest was investigated by the use of SYBR green 
quantitative real time PCR (qRT-PCR). This method quantifies the gene of interest by 
the detection of the incorporated DNA-intercalating fluorescent dye SYBR green 
during synthesis using the 7500 Real Time PCR systems. By accumulation of the PCR 
product, the detectable fluorescence was amplified by each PCR cycle. The relative 
expression level was determined by normalization to GAPDH with results presented 
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as fold expression according to the following formula (CT is the threshold cycle value):  
relative mRNA expression = 2–(CT of gene of interest – CT of GAPDH). 
Reactions were carried out in a volume of 25µl in duplicates. 
Reaction mix:  
1x SYBR green mix (ready to use) 
900 pmol forward primer 
900 pmol reverse primer  
H2O 
template complementary DNA  
The SYBR green mix contains SYBR green, MgCl2, dNTP, Hot Gold Star Taq 
polymerase and uracil-N-glycosylase.  
2.2.12 Immunofluorescent staining for flow cytometry 
For the detection of CD95L on human and murine T cells, cell pellets containing 0.5-5 
x 105 cells were resuspended in a mixture containing 10µg/ml biotinylated anti-
CD95L or isotype mAb for 60 min in FACS buffer (all steps were carried out at 4°C). 
After washing with FACS buffer,  the cell pellet was resuspended in FACS buffer 
containing streptavidin-APC and incubated for 30 min Cells were washed with FACS 
buffer and then incubated with reagent 1 and Fc- receptor blocker in FASER buffer 
for 10 min After a wash with FASER buffer, cells were resuspended in FASER buffer 
containing reagent 2 and Fc- receptor blocker for 10 min If needed for investigation, 
different fluorescentlymarked antibodies for the staining of other cell surface 
molecules were added during this final step. Finally, cells were washed with FASER 
buffer and resuspended in FASER buffer for measurement. 
For the immunofluorescent staining of other cell surface molecules than CD95L, 0.5-5 
x 105 cells were pelleted, resuspended in a mix of different fluorescently marked 
antibodies in FACS buffer and incubated at 4°C for 20-60 min After incubation, cells 
were washed with FACS buffer  and resuspended in FACS buffer for measurement.  
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The investigation of the intracellular protein Foxp3 in human T cells was carried out 
according to the manufacturer’s protocol at 4°C. Briefly, 1-5 x 106 cells were washed 
with PBS, and incubated for 30-60 min in Fixation/Permeabilization Buffer. After a 
wash with PBS, cells were centrifuged twice with Permeabilization Buffer. Cell pellets 
were incubated in Permeablization Buffer containing normal mouse serum for 15 min 
(blockage of inspecific binding sites). PE-coupled anti-Foxp3 or isotype mAb was 
added and the mix was incubated for an additional 30 min. Subsequently, cells were 
washed twice with Permeabilization Buffer and resuspended in PBS for measurement 
at the flow cytometer.  
Mean fluorescence intensity (MFI) increase in % was calculated according to the 
following formula: increase in MFI (%) = [(MFIstimulated − MFIunstimulated)/MFIunstimulated] × 100 
2.2.13 RNA interference  
Human CD4+CD25- and CD4+CD25++ T cells were electroporated in supplemented 
human T cell nucleofection solution containing 1µM control siRNA or Foxp3-specific 
siRNA. After 72 hr, the cells were divided to confirm the knock-down of Foxp3 by 
flow cytometry on the one hand and to investigate CD95L expression after stimulation 
on the other hand.  
2.2.14 Mice 
Mice (C57/BL6, lpr, Foxp3.DGL, Foxp3.DGL x lpr, RAG2-/-, RAG2-/- x lpr) were 
housed under specific-pathogen-free conditions at the central animal facility of the 
German Cancer Research Center, and experiments were according to institutional 
guidelines and regulations. Organs of DEREG and Scurfy x DEREG mice were 
obtained from Tim Sparwasser, Twincore, Medical School Hanover.  
2.2.15 BM chimeric mice 
For BM chimeric mice, donor BM cells were T cell-depleted to prevent donor T cell-
mediated graft vs. host disease (GvHD) which might interfere with the engraftment 
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process. Therefore, BM cells isolated from femur and tibia of donor mice, were 
subjected to MACS to obtain T cell-depleted BM. BM cells were incubated with a 
FITC-labeled anti-mouse CD3 mAb, washed and subsequently incubated with anti-
FITC beads. CD3+ T cells are retained in the column, while the remaining BM cells 
flow through. 3-6 x 106 T cell-depleted donor BM cells were injected into sublethally 
irradiated (4.5 Gy) 5-8 week old RAG2-/- x lpr mice. Donors were gender matched 
Foxp3.DGL and Foxp3.DGL x lpr mice. 
2.2.16 In vivo luciferase measurement 
6-10 weeks after BM reconstitution, experiments were carried out. Mice were injected 
i.p. with 0.25µg/g body weight anti-CD95 mAb (Jo2) and specific isotype control (Yin 
et al., 1999). As control, 12ng/g body weight DT was injected i.p. For the detection of 
luciferase activity, mice were injected i.p. with 4.5 mg luciferin in 200µl PBS. After an 
incubation period of at least 5 min, luminescent pictures were taken with the IVIS 100 
Imaging System. Data was analyzed by means of the Igor Pro 4.09A software. The 
relative light unit (RLU) values were normalized to the isotype control according to 
the following formula: (RLUtreatment 0/24/48hr/RLUtreatment 0hr)/ (RLUisotype 0/24/48hr/RLUisotype 0hr) 
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3 Results 
3.1 In vitro studies  
Previous in vitro experiments demonstrated a high sensitivity of human Treg to 
apoptosis induced by direct stimulation of CD95 (Aswad et al., 2005; Fritzsching et al., 
2005). Nevertheless, Treg are resistant to AICD which is characterized by TCR 
stimulation-induced expression and subsequent binding of CD95L to CD95 (Alderson 
et al., 1995; Klas et al., 1993; Krueger et al., 2003a). Due to the fact that a functional 
CD95-triggered death pathway exists in Treg, their resistance to AICD suggests 
insufficient CD95L levels, which can have several reasons. For example, stimulation-
induced CD95L expression could be diminished or CD95L cleavage from the cell 
surface could be enhanced. Therefore, the in vitro studies aim to investigate CD95L 
levels in Treg.   
3.1.1 Human Treg express low CD95L mRNA compared to Tcon  
CD95L protein expression upon TCR stimulation is required for the execution of 
AICD. Absent CD95L mRNA results in CD95L protein deficiency and might cause the 
resistance of Treg to AICD. Thus, CD95L mRNA expression was investigated in Treg 
compared to Tcon isolated from human blood. Basal CD95L mRNA expression was 
only slightly different in day 0 and day 6 Treg compared to day 0 and day 6 Tcon, 
respectively (Fig. 3.1.1). However, stimulation-induced CD95L mRNA expression 
revealed differences between Treg and Tcon. While day 0 Treg showed almost no 
increase over basal CD95L mRNA levels upon stimulation with pb anti-CD3 mAb or 
the strong stimulus PMA/Ionomycin (P/I), day 0 Tcon showed a stimulation-
dependent increase of CD95L mRNA (Fig. 3.1.1 a). Stimulation of Tcon with pb anti-
CD3 mAb marginally increased CD95L mRNA whereas P/I treatment led to 
substantially elevated CD95L mRNA compared to unstimulated or DMSO-treated 
cells (Fig. 3.1.1 a).  
On day 6 of culture, induction of CD95L expression was still low in Treg irrespective 
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of stimulation with pb anti-CD3 mAb or P/I (Fig. 3.1.1 b). Tcon in contrast showed 
considerable CD95L mRNA upregulation after treatment with pb anti-CD3 mAb 
which was comparable to P/I stimulation-induced CD95L mRNA (Fig. 3.1.1 b). In 
conclusion, freshly isolated as well as expanded human Treg showed low CD95L 
mRNA induction upon stimulation which indicates that stimulation-dependent 
CD95L mRNA expression is severely blocked in human Treg.  
 
Figure 3.1.1│ Human Treg have low CD95L mRNA compared to Tcon after 
stimulation. a Day 0 Treg and Tcon were left unstimulated (-) or incubated for 2 hr with 
30µg/ml pb anti-CD3 mAb, DMSO or 10ng/ml PMA plus 1µM Ionomycin. RNA was isolated from 
cell lysates and reverse transcribed using oligo dT primers. CD95L mRNA expression was 
quantified by detection of incorporated SYBR green. The relative expression level was determined 
by normalization to GAPDH with results presented as fold expression compared to unstimulated 
Tcon. b Experiment as in a except with Treg and Tcon cultured for 6 days in vitro with soluble 
anti-CD3 mAb, anti-CD28 mAb and IL-2. Data are representative of 3 independent experiments. 
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3.1.2 Establishment and evaluation of a CD95L amplification protocol 
To confirm that the low amount of CD95L mRNA in Treg cannot give rise to a 
substantial amount of CD95L protein in Treg, a reliable method for the detection of 
CD95L protein on the cell surface was needed. The commonly used flow cytometry 
protocol (hereafter referred to as “regular staining”) makes use of a biotinylated anti-
CD95L mAb (step 1) followed by an APC-coupled streptavidin (step 2) to detect 
CD95L on the cell surface (Fig. 3.1.2 a and b). This method inadequately visualizes 
CD95L on the cell surface of primary T cells and is not sensitive enough to compare 
CD95L expression of Tcon vs. Treg. To improve the existing protocol, different signal 
amplification methods were tested. Finally, the Fluorescence Amplification by 
Sequential Employment of Reagents (FASER) kit by Miltenyi Biotec proved of value 
for the detection of CD95L. For the new protocol, the regular staining is followed by 
two additional steps (step 3 and 4) of the FASER kit to amplify the CD95L surface 
signal (fig 3.1.2 a and c). In step 3, a biotinylated anti-APC mAb binds to the APC-
coupled streptavidin. This step is followed by an additional streptavidin-APC which 
binds to the biotinylated anti-APC mAb (step 4).  
The specificity of the established amplification protocol for the detection of CD95L 
surface protein was tested with the erythroleukemic cell line K562 (CD95L negative) 
and the K562-derived cell line KFL9 (CD95L overexpressing K562). As seen in Fig. 
3.1.2 d, the signal for the CD95L protein on KFL9 cells was enhanced by the FASER 
method compared to the regular staining. The amplified signal was specific as the 
FASER method did not result in any signal on K562 cells (Fig. 3.1.2 d). 
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Figure 3.1.2│ CD95L amplification protocol for flow cytometry. a The regular 
staining detects cell surface CD95L expression by a biotinylated anti-CD95L antibody in a first 
step, followed by streptavidin-APC in step 2. The signal amplification by the FASER kit is achieved 
by two additional steps. In step 3, biotinylated anti-APC mAb binds to the APC-coupled 
streptavidin. This biotinylated mAb is bound by streptavidin-APC in step 4. b The regular staining 
amplifies the signal to some extent. c The use of the regular staining together with the FASER kit 
largely amplifies the signal for CD95L. d KFL9 (CD95L overexpressing K562) cells were stained 
according to the regular staining (-FASER). KFL9 or K562 (which are CD95L negative) cells were 
stained according to the new amplification protocol (+FASER) to evaluate the amplification 
potential and the specificity of the FASER kit. Data are representative of 2 independent 
experiments. 
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3.1.3 Human Treg express less CD95L protein compared to Tcon 
As shown in Fig. 3.1.1, a small induction of CD95L mRNA in stimulated vs. not 
stimulated Treg was observed. This low amount of mRNA might lead to substantial 
CD95L protein. Hence, the CD95L surface protein level was investigated in Treg by 
the aforementioned FASER amplification method. 20 hr after pb anti-CD3 mAb, 
CD95L expression was not altered in day 0 Treg compared to isotype treated cells 
(Fig. 3.1.3, upper panel). Stimulation by P/I could also not increase CD95L surface 
expression in Treg (Fig. 3.1.3, upper panel). Contrary to Treg, day 0 Tcon showed 
elevated surface CD95L protein expression by P/I treatment, while no increased 
CD95L protein expression was observed after pb anti-CD3 mAb stimulation 
compared to isotype or DMSO treated cells. On day 6, only a small subpopulation of 
pb anti-CD3 mAb treated Treg induced CD95L protein (Fig. 3.1.3, lower panel). This 
subpopulation of CD95L positive Treg was slightly increased after the strong P/I 
stimulus compared to pb anti-CD3 mAb stimulation (Fig. 3.1.3, lower panel). 
Expanded Tcon could produce CD95L protein after pb anti-CD3 mAb (which is 
absent in freshly isolated Tcon) as well as after P/I stimulation (Fig. 3.1.3 , lower 
panel). Together, these results demonstrate that human Treg have very low CD95L 
Figure 3.1.3│ Treg have low CD95L surface protein compared to Tcon. Day 0 or 
day 6 Treg and Tcon were incubated for 20 hr with 30µg/ml pb isotype control, pb anti-CD3 
mAb, DMSO or 10ng/ml PMA plus 1µM Ionomycin. CD95L surface protein expression was 
detected using the FASER amplification protocol. Data are representative of 3 independent 
experiments. 
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protein expression at a time point at which Tcon are already highly positive.  
3.1.4 Naïve/resting human Treg express low levels of CD95L protein 
CD95L expression in T cells is influenced by the cellular activation status. While 
activated T cells express CD95L after short stimulation periods, naïve T cells have to 
be stimulated repeatedly to induce CD95L expression (Strasser and Pellegrini, 2004). 
Whereas naïve CD4+ T cells are characterized by high CD45RA and low CD45RO 
expression, activated/memory CD4+ T cells are CD45RAlo and CD45ROhi. In general, 
most Treg in adults have an activated/memory phenotype due to recognition of self-
Ag (Fig. 3.1.4 a). Tcon from adult blood donors contain naïve (CD45RAhi CD45ROlo) 
as well as activated cells (CD45RAlo CD45ROhi) which arise from continuous contact 
to environmental pathogens (Fig. 3.1.4 a). Treg from cord blood, in contrast to Treg 
from adult blood, are almost exclusively naïve/resting which is reflected by the 
expression of high amounts of CD45RA and low CD45RO (Fig. 3.1.4 a). Like cord 
blood Treg, cord blood Tcon also have a mostly naïve phenotype (Fig. 3.1.4 a). To 
exclude that the activated/memory status of adult blood Treg is involved in low 
CD95L expression, naïve cord blood Treg were investigated regarding CD95L 
expression. Similar to Treg from adult blood, freshly isolated cord blood Treg 
produced only minimal amounts of CD95L protein upon stimulation with both pb 
anti-CD3 mAb and P/I (Fig. 3.1.4 b, upper panel). Day 0 Tcon from cord blood 
induced CD95L upon P/I treatment comparable to Tcon from adult blood (Fig. 3.1.4 b, 
upper panel.  
On day 6 of culture, almost no cord blood Treg, like Treg in adults, showed CD95L 
expression upon pb anti-CD3 mAb stimulation (Fig. 3.1.4 b, lower panel). Few CD95L-
positive Treg were detected after P/I stimulation (Fig. 3.1.4 b, lower panel). In contrast 
to Treg, day 6 Tcon from cord blood, like Tcon from adult blood, showed high CD95L 
expression upon pb anti-CD3 mAb and P/I treatment (Fig. 3.1.4 b, lower panel). 
Hence, the activation status of human Treg is not the reason for the low CD95L 
expression in human Treg.  
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3.1.5 Kinetics of CD95L expression in human Treg 
Low amounts of CD95L protein were detected on the cell surface of Treg at the same 
time point when Tcon showed high CD95L expression (20 hr after stimulation). 
Nevertheless, the possibility remains that CD95L surface protein expression follows 
different kinetics in Treg compared to Tcon.  
Therefore, CD95L protein expression in Treg was investigated at different time points 
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Figure 3.1.4│ Cord blood Treg express low CD95L after stimulation. a Treg and 
Tcon from adult or cord blood were analyzed for the expression of CD45RA and CD45RO. b Day 
0 or day 6 cord blood Treg and Tcon were incubated for 20 hr with 30µg/ml pb isotype control, 
pb anti-CD3 mAb, DMSO or 10ng/ml PMA plus 1µM Ionomycin. CD95L surface protein expression 
was detected with the help of the FASER amplification protocol. Data are representative of 2 
independent experiments. 
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after stimulation (Fig. 3.1.5 a). In the previously shown experiments, CD95L protein 
expression was investigated 20 hr after stimulation. To exclude different CD95L 
protein expression kinetics of Treg, further time points after stimulation (0.5, 10 and 
40 hr) were examined. It has been published that surface CD95L protein increases 20-
40 min after stimulation in pre-activated cells due to release from cellular granules 
(Schulte et al., 2007). As described in the previous paragraph, most Treg from adult 
blood have an activated/memory phenotype which makes the storage of CD95L 
protein likely and prompted the investigation of earlier stimulation time points. After 
30 min of stimulation with pb anti-CD3 mAb as well as P/I which should release 
stored CD95L protein to the cell surface of pre-activated cells, day 0 Treg did not 
increase CD95L surface protein (Fig. 3.1.5 a, left). Also naïve/resting day 0 Tcon did 
not show a stimulation-dependent increase of CD95L expression 30 min after pb anti-
CD3 mAb and P/I (Fig. 3.1.5 a, left). Furthermore, one additional early (10 hr) and one 
later time point (40 hr)  of stimulation were tested. Stimulation of day 0 Treg for 10, 20 
or 40 hr with either pb anti-CD3 mAb or P/I did not highly upregulate CD95L 
expression (Fig. 3.1.5 a, left). However, CD95L surface protein expression could be 
detected in day 0 Tcon between 10 and 40 hr after P/I stimulation with a peak of 
expression at 20 hr (Fig. 3.1.5 a, left). Pb anti-CD3 mAb could not induce CD95L 
surface protein in day 0 Tcon at any time point after stimulation (Fig. 3.1.5 a, left).  
Despite the activated/memory phenotype of Treg, the in vitro expansion protocol 
might activate them even further and by that trigger CD95L expression. For that also 
CD95L protein expression in day 6 T cells at different time points after stimulation 
was investigated. Treg did not show an increase in CD95L surface protein expression 
at early as well as late stimulation periods with pb anti-CD3 mAb (Fig. 3.1.5 a, right). 
The stimulation with P/I could marginally increase CD95L surface expression in Treg 
at the latest tested time point (40 hr). The investigation of CD95L expression in day 6 
Tcon upon pb anti-CD3 mAb revealed no detectable levels after a 30 min stimulation 
(Fig. 3.1.5 a, right). Nevertheless, CD95L expression increased time-dependently 
between 10 and 40 hr after stimulation in Tcon (Fig. 3.1.5 a, right). Tcon also produced 
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CD95L protein when stimulated with P/I, but this stimulus did not increase CD95L 
levels to the same extent as pb anti-CD3 mAb stimulation (Fig. 3.1.5 a, right). 
Although there was no large difference in CD95L protein expression detected in Treg 
after different stimulation periods, it has to be considered that Treg could express 
CD95L protein at different days of in vitro culture compared to Tcon. On this account, 
Treg were stimulated at different time points (day 0 to 6) of in vitro culture for 20 hr 
and CD95L expression was analyzed. On all days of culture, pb anti-CD3 mAb could 
not induce substantial CD95L surface protein expression. In addition, the stimulation 
with P/I for 20 hr did not lead to an increase in surface CD95L expression in Treg 
over time (Fig. 3.1.5 b). Stimulation-dependent CD95L expression was also 
investigated in Tcon at each day of in vitro culture. At all investigated time points, 
Tcon produced similar CD95L protein levels upon a 20 hr P/I stimulation (Fig. 3.1.5 
b). CD95L protein expression upon pb anti-CD3 mAb stimulation could not be 
detected from day 0 to 2 of in vitro culture. However, on day 3 of culture, a 20 hr 
stimulation with pb anti-CD3 mAb induced CD95L protein expression levels in Tcon 
which were comparable to P/I treatment-induced CD95L protein expression. On day 
4 of culture, CD95L expression increased to approximately 3-fold over P/I treatment 
and reached more than 6-fold higher levels on day 5 and 6 compared to P/I 
stimulation (Fig. 3.1.5 b).  
All together, these results show that human Treg display no altered CD95L expression 
kinetics and imply an impairment of human Treg to induce CD95L surface protein 
expression.  
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Figure 3.1.5│ CD95L expression kinetics in Treg and Tcon. a Day 0 or day 6 Treg 
and Tcon were incubated for the indicated time points with 30µg/ml pb isotype control, pb anti-
CD3 mAb, DMSO or 10ng/ml PMA plus 1µM Ionomycin. CD95L surface protein expression was 
detected according to the FASER amplification protocol. b At different days of in vitro culture 
Treg and Tcon were incubated for 20 hr with the stimuli explained in a and stained according to 
the FASER amplification protocol. Data are representative of 2 independent experiments. 
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3.1.5 CD95L cleavage is not causative for low CD95L expression of human Treg 
Different metalloproteases can cleave CD95L from the cell surface to release a soluble 
form which has less apoptotic potential than the membrane bound form (Schulte et 
al., 2007; Schneider et al., 1998; Hohlbaum et al., 2000). Among these metalloproteases, 
ADAM-10 was reported to play an important role in T cells (Schulte et al., 2007). 
Increased cleavage of CD95L protein from the cell surface caused by higher ADAM-10 
activity could be a potential cause for the low CD95L protein expression of Treg. For 
that reason, CD95L cleavage was investigated. Incubation with a specific ADAM-10 
peptide inhibitor during stimulation had no effect on CD95L expression in day 0 Treg 
upon stimulation with pb anti-CD3 mAb (Fig. 3.1.6, upper panel). CD95L expression 
was also not altered in P/I-treated Treg incubated with an ADAM-10 inhibitor (Fig. 
3.1.6, upper panel). Pb anti-CD3 mAb and P/I stimulated day 0 Tcon only marginally 
increased CD95L expression upon treatment with an ADAM-10 inhibitor (Fig. 3.1.6, 
upper panel). When day 6 Treg were incubated with an ADAM-10 inhibitor during 
stimulation, the level of CD95L protein was unchanged in inhibitor-treated compared 
to untreated cells upon stimulation (Fig. 3.1.6, lower panel). CD95L surface protein 
expression was similar in day 6 Tcon irrespective of incubation with an ADAM-10 
inhibitor in the case of pb anti-CD3 mAb treatment (Fig. 3.1.6, lower panel). However, 
ADAM-10 inhibitor-treated day 6 Tcon showed a marginal increase in CD95L 
expression upon P/I stimulation compared to cells not treated with inhibitor (Fig. 
3.1.6, lower panel).  
The fact that the inhibition of the metalloprotease ADAM-10 does not increase CD95L 
expression in human Treg excludes CD95L cleavage as a reason for low CD95L 
surface protein in Treg. 
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3.1.7 Knock-down of Foxp3 in human Treg increases CD95L expression  
The data shown in the previous paragraphs demonstrate a low CD95L expression by 
human Treg. One factor that might be responsible for the low CD95L expression in 
Treg is the TF Foxp3.  Foxp3 is highly expressed in Treg and can bind together with 
other transcriptional regulators to the promoter of cytokines like IL-2 and repress 
transcription (Wu et al., 2006; Fontenot et al., 2003; Chen et al., 2006; Khattri et al., 
2003). In a genome-wide analysis of Foxp3 target genes, Zheng et al. found that Foxp3 
is able to bind to the CD95L gene (Zheng et al., 2007b).  
Figure 3.1.6│ ADAM-10 cleavage does not cause low CD95L levels on Treg. Day 
0 or day 6 Treg and Tcon were incubated for 20 hr with 30µg/ml pb isotype control, pb anti-CD3 
mAb, DMSO or 10ng/ml PMA plus 1µM Ionomycin in the presence or absence of 1µM ADAM-10 
inhibitor. CD95L surface protein expression was detected using the FASER amplification protocol. 
Data are representative of 2 independent experiments. 
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To investigate if Foxp3 negatively regulates CD95L expression in Treg, knock-down 
experiments were performed. Foxp3 protein expression was substantially down-
regulated in Treg 72 hr after transfection with a Foxp3-specific siRNA (siFoxp3) while 
the scrambled control siRNA (siCtrl) could not down-regulate Foxp3 expression (Fig. 
3.1.7 a and b).. To test CD95L protein expression, cells were stimulated 72 hr after 
Foxp3 knock-down with P/I for 20 hr. An approximately two fold increase of CD95L 
protein expression in siFoxp3 to control transfected Treg could be observed after 
stimulation with P/I while treatment of Tcon with the specific siRNA against Foxp3 
did not alter their CD95L protein expression after stimulation (Fig. 3.1.7 c). Although 
CD95L protein expression was increased by the knock-down of Foxp3, the CD95L 
protein levels produced by Treg did not reach Tcon levels 72 hr after Foxp3 knock-
down (Fig. 3.1.7 c). The difference between CD95L expression of Treg compared to 
Tcon might be due to residual Foxp3 protein after knock-down. However, this result 
clearly allots a role to Foxp3 in the repression of CD95L expression in human Treg.  
 
Results 
 56 
Figure 3.1.7│ Foxp3 knock-down leads to increased CD95L expression in 
human Treg after stimulation. a Foxp3 expression levels of day 0 Treg and Tcon 72 hr 
after siCtrl or siFoxp3 transfection detected by intracellular flow cytometry. b Quantification of 
Foxp3 protein expression 72 hr after knock-down in day 0 Treg and Tcon. c 72 hr after 
transfection, day 0 Treg and Tcon were stimulated for 20 hr with DMSO or 10ng PMA plus 1µM 
Ionomycin. Surface CD95L protein expression was investigated according to the amplification 
protocol and calculated as MFI increase of CD95L compared to isotype stained cells. Data are 
representative of 3 independent experiments. 
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Figure 3.1.8│ Murine Treg express low CD95L protein after stimulation. Freshly 
isolated Treg and Tcon isolated from B6 wt mice were stimulated for 20 hr with 3µg/ml pb 
isotype, pb anti-CD3 mAb, DMSO or 10ng PMA plus 1µM Ionomycin. CD95L surface expression 
was analyzed by the use of the FASER amplification method. Data are representative of 2 
independent experiments. 
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3.1.8 Murine Treg express less CD95L protein compared to Tcon 
In addition to the human system, Treg and Tcon isolated from C57/Black6 (B6) wt 
mice were analyzed for CD95L protein expression. Freshly isolated murine Treg, like 
human Treg, failed to induce substantial CD95L protein upon pb anti-CD3 mAb (Fig. 
3.1.8). Stimulation with P/I could also not induce CD95L protein in murine Treg 
which is comparable to Treg in the human system (Fig. 3.1.8). Day 0 murine Tcon 
could produce CD95L upon P/I treatment comparable to human Tcon (Fig. 3.1.8). 
However, in contrast to human day 0 Tcon which did not upregulate CD95L 
expression upon pb anti-CD3 mAb, murine day 0 Tcon displayed CD95L protein on 
the cell surface after stimulation with pb anti-CD3 mAb (compare Fig. 3.1.3 with Fig. 
3.1.8). As the physiological stimulus pb anti-CD3 mAb induced CD95L expression in 
murine day 0 Tcon, CD95L expression was investigated exclusively in murine day 0 T 
cells. The obtained data regarding CD95L expression in murine Treg demonstrate 
that, like in the human system, Treg isolated from mouse have low stimulation-
dependent CD95L protein expression.  
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3.1.9 Murine Foxp3-deficient Treg express CD95L  
As shown before (Fig. 3.1.7), Foxp3 knock-down in human Treg led to an increased 
CD95L expression compared to control siRNA treated Treg after stimulation. 
However, CD95L expression levels in Foxp3 down-regulated Treg did not reach 
expression levels of Tcon which might be due to the residual Foxp3 protein expression 
in Treg after knock-down. To further clarify the role of Foxp3 in CD95L repression, 
Foxp3-deficient scurfy mice were investigated. The scurfy mouse strain harbors a 
spontaneous Foxp3 mutation leading to an incomplete mRNA and an unstable Foxp3 
protein. As a consequence, Treg of these mice lack Foxp3 and can therefore not be 
isolated and investigated. To enable the analysis of Foxp3-deficient so called “would-
be” Treg of scurfy mice, this strain was crossed with Depletion Of Treg (DEREG) 
mice. The DEREG mouse strain contains a construct in which a green fluorescent 
protein (GFP) - DT receptor (DTR) fusion protein is driven by an additional Foxp3 
promoter. Since the Foxp3 promoter is only active in Treg, Treg from DEREG mice are 
GFP-DTR positive. On the basis of GFP expression, Treg can be distinguished from 
other CD4+ cells by flow cytometry while they can be depleted by the injection of DT 
into living mice. Despite the mutated non-functional Foxp3 in Treg of scurfy mice the 
Foxp3 promoter is active. “would-be” Treg of scurfy x DEREG mice express the GFP-
DTR fusion protein controlled by the additional Foxp3 promoter activity and can 
therefore be traced by GFP expression (Lahl et al., 2007). This makes it possible to 
investigate the effect of Foxp3 deficiency on CD95L expression in Treg.  
CD4+ T cells were isolated from spleens and pooled lymph nodes (LN) of scurfy x 
DEREG and control DEREG mice and stimulated for 20 hr with pb anti-CD3 mAb. As 
shown in Fig. 3.1.8, the stimulation of murine day 0 Tcon with pb anti-CD3 mAb 
induces high amounts of CD95L surface protein (in contrast to human Tcon which 
stay CD95L negative upon pb anti-CD3 mAb on day 0). Therefore, this more 
physiological stimulus and not the strong stimulus P/I was used. By gating on GFP- 
(Tcon) and GFP+ (Treg) cells, CD95L protein expression could be investigated in the 
two cell populations. Comparable to murine wt Treg (and human Treg), Treg from 
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DEREG mice failed to produce CD95L upon stimulation with pb anti-CD3 mAb (Fig. 
3.1.9). Tcon from DEREG mice were able to induce CD95L expression upon pb anti-
CD3 mAb stimulation (Fig. 3.1.9). Interestingly, Foxp3-deficient “would-be” Treg 
from scurfy x DEREG mice produced CD95L protein in amounts comparable to Tcon 
from scurfy x DEREG and wt DEREG mice (Fig. 3.1.9). Together with the data 
obtained by Foxp3 knock-down in human Treg, these results strengthen the role of 
Foxp3 in the negative regulation of CD95L expression in Treg. 
 
 
Figure 3.1.9│ CD95L 
expression is high in Foxp3-
deficient scurfy x DEREG 
“would-be” Treg after 
stimulation.   
MACS sorted CD4+ T cells from 
DEREG and scurfy x DEREG mice 
were stimulated for 20 hr with 
3µg/ml pb isotype control or pb 
anti-CD3 mAb. Cells were stained 
for CD95L with FASER 
amplification protocol. GFP+ (Treg) 
and GFP- (Tcon) were gated and 
analyzed for CD95L expression. 
Data are representative of 3 
CD95L surface protein
isotype anti-CD3
DEREG Treg
DEREG Tcon
scurfy x DEREG Treg
scurfy x DEREG Tcon
0
100
200
400
300
M
FI
 in
cr
ea
se
CD
95
L 
vs
.is
ot
yp
e
(%
)
Results 
 60 
3.2 In vivo studies 
Human Treg express the death receptor CD95 on the cell surface and are highly 
sensitive to apoptosis induced by exogenous CD95L in vitro (Fritzsching et al., 2005). 
Murine Treg in tumors can be depleted by CD95 stimulation and by CD95L+ cells 
during ongoing colitis (Reardon et al., 2008; Chen et al., 2007). However, the 
sensitivity of Treg to CD95-induced apoptosis in healthy mice in the absence of an 
immune reaction remains elusive. The in vivo studies therefore aim to investigate, 
with the help of a suitable mouse model, whether Treg are sensitive to CD95-induced 
apoptosis per se and can be depleted by CD95 engagement in vivo.  
3.2.1 Characterization of RAG2-/- x lpr mice 
For the in vivo experiments in the follwing paragraphs, RAG2-/- x lpr mice were used. 
These were obtained by crossing RAG2-/- and lpr mice (both on the B6 background). 
Lpr mice have a mutation in the CD95 gene which leads to a decreased expression of 
CD95 on the cell surface. Among other symptoms, these mice develop 
lymphadenopathy and splenomegaly caused by increased numbers of aberrant CD3+ 
B220+ CD4- CD8- T lymphocytes. RAG2-/- mice have negligible numbers of 
lymphocytes due to a deficiency in RAG2, an enzyme needed for the recombination of 
the receptor genes of T and B lymphocytes which is reflected by a size reduction of 
their lymphatic organs. To investigate if the residual T and B cells in RAG2-/- x lpr 
mice can give rise to aberrant CD3+ B220+ T cells and lead to lymphadenopathy and 
splenomegaly, T and B cell markers as well as spleen and LN of RAG2-/- x lpr mice 
were compared to B6 control mice, RAG2-/- and lpr mice. B6 mice had normally sized 
spleen and LN, whereas the organs of RAG2-/- were reduced in size (Fig. 3.2.1 a). Lpr 
mice, in contrast, had enlarged spleen and LN (Fig. 3.2.1 a). The characterization of 
RAG2-/- x lpr mice showed that spleens and LN were similarly small as organs from 
RAG2-/- mice (Fig. 3.2.1 a). By flow cytometry, normal numbers of CD3+ T cells and 
B220+ B cells were detectable in spleens of B6 control mice, whereas RAG2-/- splenic 
mononuclear cells, as expected, contained reduced numbers of T and B cells. Both 
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mouse strains did not have elevated numbers of aberrant T lymphocytes. Lpr mice, 
displayed increased levels of aberrant T cells (Fig. 3.2.1 b). Interestingly, the residual T 
and B cells of RAG2-/- x lpr mice did not give rise to CD3+ B220+ T cells (Fig. 3.2.1 b). 
Similar results regarding CD3+ and B220+ cells were obtained with cell preparations 
from LN of the different mouse strains (data not shown). These results demonstrate 
that although RAG2-/- x lpr mice harbor the mutated form of CD95 the residual T and 
B cells do not give rise to aberrant CD3+ B220+ T cells.   
 
 
Figure 3.2.1│Characterization of RAG2-/- x lpr mice. a LN (axillary, lateral axillary, 
inguinal, mesenteric, sacral) and spleens isolated from B6, RAG2-/-, lpr and RAG2-/- x lpr mice. b 
Splenic mononuclear cells were stained for CD3 and B220 and analyzed by flow cytometry to 
detect T cells, B cells and aberrant CD3+ B220+ T cells. Data are representative of 2 independent 
experiments. 
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3.2.2 Establishment of BM chimeric RAG2-/- x lpr mice  
To investigate the sensitivity of Treg to CD95-induced apoptosis in vivo, a BM 
chimeric mouse model was established. Upon injection of anti-CD95 mAb, CD95 wt 
Foxp3.DGL mice (this mouse strain will be explained below) die by liver failure while 
lpr mice survive owing to low CD95 expression caused by mutated CD95 (Fig. 3.2.2 a) 
(Kaufmann et al., 2007; Ogasawara et al., 1993). Although lpr mice survive the 
injection with anti-CD95 mAb, the role of CD95 cannot be investigated as all cells lack 
functional CD95 (Fig. 3.2.2 a). BM chimeric mice, in which the host is deficient in 
CD95 (lpr) and the donor lymphocytes express CD95, are suitable to answer the 
question if Treg are sensitive to CD95-induced apoptosis in vivo (Fig. 3.2.2 a). As host 
mice, RAG2-/- x lpr mice which do not die upon injection of anti-CD95 and cannot 
produce lymphocytes themselves were used as recipients of BM transplants (Fig. 3.2.2 
a).  
Sublethal irradiation partially depletes BM cells in the recipient and opens niches for 
the BM graft. Although the donor BM will reconstitute only a part of the BM in the 
RAG2-/- x lpr recipient mouse it will give rise to the entire lymphocyte pool as the host 
BM lacks RAG2.  
Foxp3.DGL mice, the BM donors, contain a bacterial artificial chromosome (BAC) in 
which the Foxp3 promoter controls the expression of three individual genes encoding 
for DTR, GFP and luciferase (different from DEREG mice which express a GFP-DTR 
fusion protein). As the Foxp3 promoter is only active in Treg, Treg of these mice 
express DTR, GFP and luciferase. Treg in Foxp3.DGL mice can therefore be depleted 
by the injection of DT while the expression of luciferase enables the detection and 
quantification of Treg by in vivo imaging in anesthetized mice upon injection of 
luciferin. In addition, Treg can be traced on the basis of GFP expression by flow 
cytometry.  
To obtain BM chimeras, irradiated RAG2-/- x lpr mice were intravenously injected 
with T cell-depleted BM from either Foxp3.DGL or Foxp3.DGL x lpr mice. The 
resulting BM chimeric RAG2-/- x lpr mice either contain T cells that are CD95 
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sufficient (Foxp3.DGL BM) or CD95-deficient (Foxp3.DGL x lpr BM) and can be used 
after a period of 6-8 weeks (donor BM engraftment period) to investigate whether 
Treg are sensitive to CD95-induced apoptosis in the absence of an immune response 
in vivo (Fig. 3.2.2 b).  
 
 
Figure 3.2.2│ Protocol for BM chimeric mice. a Effect of the injection of an agonistic 
anti-CD95 mAb into different mouse strains. Only RAG2-/- x lpr mice with Foxp3.DGL BM can be 
used for the investigation of CD95 in Treg. b 5-8 week old RAG2-/- x lpr mice were sublethally 
irradiated and received one day later an i.v. injection containing 1-5 x 106 CD3-depleted BM cells 
from either Foxp3.DGL or Foxp3.DGL x lpr mice. 6-8 weeks after BM transfer, mice were i.p. 
injected with an isotype control or an anti-CD95 mAb. Treg numbers were monitored between 0 
and 48 hr after treatment in vivo and ex vivo. 
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3.2.3 Depletion of Treg by CD95 stimulation  
The sensitivity of Treg to CD95-induced apoptosis has not yet been investigated in 
healthy mice. Therefore, in the following experiments, the sensitivity of Treg to CD95-
induced apoptosis in vivo in non-infected healthy mice was examined. BM chimeric 
RAG2-/- x lpr mice engrafted with Foxp3.DGL or Foxp3.DGL x lpr BM display 
luciferase activity exclusively in Treg. Mice were injected i.p. with an isotype control 
mAb, anti-CD95 mAb or DT (Treg depletion control). Before (0 hr) and 24 and 48 hr 
after treatment, luciferase activity was monitored by in vivo imaging. RAG2-/- x lpr 
chimeras that had received Foxp3.DGL BM (hereafter abbreviated as Foxp3.DGL  
RAG2-/- x lpr) had lower luciferase activity levels after injection of anti-CD95 mAb 
compared to isotype treated mice (Fig. 3.2.3 a and b). The detected luciferase activity 
was lower after 24 hr of treatment with anti-CD95 mAb and started to rise again after 
48 hr in one mouse whereas it remained almost identically low at both time points in 
the other mouse treated with anti-CD95 mAb (Fig. 3.2.3 b). The level of luciferase 
activity did not decrease in Foxp3.DGL x lpr  RAG2-/- x lpr mice, in which the T 
cells are CD95-deficient, independent of treatment with isotype or anti-CD95 mAb 
(Fig. 3.2.3 a and b). Luciferase activity even increased in Foxp3.DGL x lpr  RAG2-/- x 
lpr mice at 24 and 48 hr after treatment compared to 0 hr (Fig. 3.2.3 b). The injection of 
DT resulted in a decrease of luciferase activity in both Foxp3.DGL  RAG2-/- x lpr 
and Foxp3.DGL x lpr  RAG2-/- x lpr BM chimeras which was more pronounced after 
24 hr (Fig. 3.2.3 a and b and data not shown). However, one can see that individual 
mice had different luciferase activity levels caused by variable degrees of BM 
chimerism (Fig. 3.2.3 a, e.g. mouse 1 and 3). 
In addition, 48 hr after treatment, the amount of GFP+ Treg was investigated in pooled 
LN (axillary, inguinal, mesenteric and sacral). It revealed that substantially less GFP+ 
Treg were present in Foxp3.DGL  RAG2-/- x lpr mice that had received anti-CD95 
mAb compared to isotype treated mice (Fig. 3.2.3 c). In contrast, GFP+ cell numbers 
remained almost constant in Foxp3.DGL x lpr  RAG2-/- x lpr mice that were treated 
with isotype or anti-CD95 mAb (Fig. 3.2.3 c). DT as positive control for the 
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depletion of Treg was able to diminish the numbers of GFP+ cells in both types of BM 
chimeras (Fig. 3.2.3 c and data not shown). Interestingly, the numbers of CD4+ GFP- T 
cells (Tcon) was only slightly altered (Fig. 3.2.3 c). These results show that Treg are not 
only in vitro sensitive to CD95-induced apoptosis but also in vivo in the absence of an 
immune response.  
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Figure 3.2.3│ Partial depletion of Treg by CD95 stimulation in vivo. a and b 
Investigation of Treg numbers by bioluminescence in vivo. a Anesthetized mice were injected 
with luciferin and in vivo bioluminescence was measured before (0 hr) and after treatment with 
isotype control (iso), anti-CD95 mAb (a-CD95) or DT (24 and 48 hr). One representative picture 
is shown. b Light output was quantified as relative light units (RLU) normalized to isotype 
control. c 48 hr after treatment, mice were sacrificed and pooled LN (inguinal, axillary, lateral 
axillary, mesenteric, sacral) were investigated for CD4+GFP+ Treg and CD4+GFP- Tcon. Isotype 
n=2 (wt, lpr), anti-CD95 mAb n=2 (wt, lpr), DT, n=2 (lpr). One of three representative 
experiments is shown.  
0
24
48
10000
8000
6000
4000
2000
Color Bar
Min = 500
Max = 10000
Foxp3.DGL Foxp3.DGL x lpr
a-CD95iso DTiso a-CD95
wt iso #1, #2/ lpr iso #1, #2
wt a-CD95 #1
wt a-CD95 #2
wt DT #1
wt DT #2
lpr a-CD95 #1
lpr a-CD95 #2
Foxp3.DGLa
hours
0
50
100
150
200
250
300
0 24 48
R
LU
 n
or
m
al
iz
ed
to
.is
ot
yp
e
(%
)
Treg
b
%
 o
f 
CD
3+
GFP- Tcon
0
10
20
30
40
iso isoa-CD95 a-CD95 DT
GFP+ Treg
0
2
4
6
8
iso a-CD95 iso a-CD95 DT
wt lpr wt lpr
c
hours
Discussion 
67 
4 Discussion 
4.1 In vitro experiments 
Treg maintain immunological self tolerance by controlling potentially hazardous self-
reactive T cells (Sakaguchi et al., 2008). Regulated proliferation and apoptosis are 
necessary to achieve equilibrated cell populations. In the context of apoptosis, several 
laboratories have demonstrated that Treg apoptosis is different in comparison to Tcon 
(Banz et al., 2002; Taams et al., 2001b; Fritzsching et al., 2005; Taylor et al., 2007). 
Effector/memory Treg, which comprise the largest fraction of Treg in adults, are 
characterized by elevated expression of CD95 and high sensitivity to apoptosis 
induced by CD95 triggering. Although Treg are sensitive to CD95-induced apoptosis, 
they cannot be killed by TCR stimulation which triggers AICD by CD95L production 
in vitro. In contrast, TCR re-stimulation induces CD95L expression in expanded Tcon 
and results in AICD (Alderson et al., 1995; Dhein et al., 1995; Klas et al., 1993; Krueger 
et al., 2003b). As the balance between Treg and effector cell subsets is important for 
initiation, course and outcome of an immune response, a detailed investigation of the 
mechanisms of Treg proliferation and death is fundamental to understand Treg 
homeostasis. The fact that Treg do not undergo AICD might be explained by 
diminished or altered CD95L expression. Therefore, the aim of the in vitro studies was 
to investigate the level of CD95L expression in Treg.  
4.1.1 Treg have low CD95L mRNA and protein levels 
The data presented in this thesis demonstrate that Treg express less CD95L mRNA 
upon stimulation compared to Tcon, irrespective if they were freshly isolated or in 
vitro expanded for 6 days (Fig. 3.1.1). In addition, the stimulus strength did not play a 
role in CD95L mRNA expression as the rather physiological stimulus pb anti-CD3 
mAb as well as the strong stimulus P/I could not substantially increase CD95L 
mRNA in Treg (Fig. 3.1.1). The obtained data are in line with mRNA array data in 
which it was shown that Treg express less CD95L mRNA than Tcon (Gavin et al., 
2002).  
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However, CD95L mRNA was not absent in Treg upon stimulation but only 
diminished. The low amount of CD95L mRNA could still result in CD95L protein 
expression. Nevertheless, investigation of CD95L surface protein expression showed 
that not only CD95L mRNA but also CD95L surface protein expression was reduced 
in Treg after stimulation (Fig. 3.1.3). This reduced CD95L expression could be 
observed in freshly isolated as well as in vitro expanded Treg. In addition, the signal 
strength, as for CD95L mRNA expression, did not play a crucial role in the 
inducibility of CD95L protein expression by Treg. In contrast, stimulation-induced 
expression of CD95L surface protein was highly upregulated in Tcon (Fig. 3.1.3).  
Although Treg showed reduced CD95L expression in all experiments, expression 
levels varied between individual experiments. These differences are probably donor-
dependent. However, CD95L mRNA and protein expression by Treg remained 
always less compared to Tcon. Moreover, on day 6 of culture, a small number of cells 
in the Treg population upregulated CD95L protein. These cells arise most likely from 
few contaminating Tcon which are present since day 0. During the culture period with 
anti-CD3/CD28 mAb and IL-2, these Tcon expand more vigorously than Treg and 
accumulate. Further cell sorting after MACS isolation to obtain even purer Treg 
populations reduced the amount of CD95L+ cells in the Treg population on day 6, 
affirming that these were contaminating Tcon (data not shown).  
Furthermore, CD95L protein expression of murine Tcon and Treg was investigated. 
Similar to the results obtained in the human system, Treg did not induce CD95L 
expression upon stimulation while Tcon became highly positive (Fig. 3.1.8). Together, 
these data imply that human as well as murine Treg are truly impaired in the 
expression of CD95L mRNA and protein.  
So far, four different studies have investigated CD95L expression by Treg in different 
experimental settings using human and murine Treg. Three of them demonstrated a 
low CD95L expression by Treg upon stimulation (Chai et al., 2002; Singh et al., 2010; 
Strauss et al., 2009). In 2002, Chai and colleages investigated murine MACS-isolated 
Treg. Upon stimulation with anti-CD3 mAb and BM-derived APC for 2 days, Tcon 
displayed intracellular CD95L expression while Treg remained negative (Chai et al., 
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2002). Furthermore, Strauss et al. investigated CD95L expression of stimulated human 
Treg sorted from peripheral blood. A 48 hr stimulation period with soluble anti-CD3 
mAb could not induce CD95L expression in human Treg. Interestingly, Treg isolated 
from patients with head and neck squamous cell cancer highly upregulated CD95L 
protein upon TCR stimulation (Strauss et al., 2009). The finding that Treg can switch 
between lack of CD95L expression in healthy donors and high CD95L expression in 
this specific cancer type, leads to the assumption that Treg might use CD95-induced 
cell death as a mechanism to kill anti-tumor effector cells. In addition, the third report 
showed that FACS-sorted murine Treg express low amounts of CD95L protein after 3 
days of stimulation with anti-CD3/CD28 mAb whereas Tcon showed high CD95L 
expression (Singh et al., 2010). In contrast to the results presented in this thesis and in 
the three described publications, a human study demonstrated that Treg can express 
CD95L. In this article, the authors found that CCR4+ Treg, which constitute the major 
part of Treg from peripheral blood, produced CD95L upon culture in medium 
containing human serum for 16 hr (Baatar et al., 2007). Three factors are conceivable 
that could account for the difference between the conflicting data and the other three 
publications and the results presented herein. In the contradictory publication, human 
serum was used as stimulus while all other experimental settings included TCR 
stimulation to trigger CD95L expression. In addition, the isolation procedure in the 
conflicting publication is more stressful as the cells are sorted by three subsequent 
isolation steps: first, cells are isolated on the basis of CD4. This is followed by a CCR4 
isolation step and finally the cells are isolated by CD25. In contrast, only 1-2 isolation 
steps were used in the other studies. Furthermore, it is difficult to judge the level of 
CD95L expression by Treg as it was not compared to Tcon. However, the authors 
show that CD95L-expressing Treg can kill Jurkat T cells in a CD95-dependent manner. 
In contrast, data obtained in this thesis show that the level of CD95L expression in 
stimulated Treg is insufficient to kill CD95-sensitive SKW B cells, while stimulated 
Tcon induce significant death (data not shown).  
The low CD95L expression by Treg after stimulation in vitro should be considered as a 
prerequisite to ensure their survival, as they would constantly commit suicide or 
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fratricide if they expressed high levels of CD95L due to their high sensitivity to CD95-
induced apoptosis. In addition, low CD95L in Treg after stimulation excludes CD95-
mediated apoptosis as mechanism by which Treg suppress responder cells. 
4.1.2 Low CD95L protein is not due to the activation status of Treg 
Due to continuous contact to self-Ag, the Treg population in human peripheral blood 
isolated from adults is mainly composed of effector/memory Treg (Fritzsching et al., 
2006). In contrast, Treg from cord blood contain a large proportion of naïve/resting 
Treg. Effector/memory and naïve/resting Treg behave differently regarding 
apoptosis. While effector/memory Treg are sensitive to CD95-mediated apoptosis, 
naïve/resting Treg are characterized by their resistance to CD95 stimulation 
(Fritzsching et al., 2006; Fritzsching et al., 2005). Owing to their resistance to CD95-
mediated apoptosis, naïve/resting Treg could use CD95L as suppressive mechanism 
as they would not commit suicide or fratricide upon expression. A difference in 
CD95L expression between naïve/resting and effector/memory Treg was therefore 
possible. Nevertheless, investigation of CD95L expression by naïve/resting Treg from 
cord blood revealed a low CD95L expression after stimulation (Fig. 3.1.4). Thus, also 
naïve/resting Treg, comparable to effector/memory Treg, cannot express high 
amounts of CD95L upon stimulation. Although CD45RA+ Treg are classified as 
naïve/resting while CD45RO+ Treg consist of effector/memory cells, there are no 
major functional differences between naïve/resting and effector/memory Treg, both 
are immunosuppressive (Valmori et al., 2005; Seddiki et al., 2006b). 
In human individuals, it has been shown that Treg have a shorter half-life compared 
to Tcon (Vukmanovic-Stejic et al., 2006). This might be due to the fact that 
effector/memory Treg are characterized by elevated expression of CD95 and high 
sensitivity to apoptosis induced by CD95 crosslinking. However, naïve/resting Treg 
are not sensitive to CD95-induced apoptosis and are spared from CD95-mediated 
apoptosis (Fritzsching et al., 2006). Despite their resistance to CD95, naïve/resting 
Treg cannot express substantial CD95L protein after stimulation. This establishes the 
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low CD95L expression as a characteristic of all Treg. 
4.1.3 Low CD95L protein is not caused by altered expression kinetics or 
increased cleavage from the cell membrane 
Although CD95L expression in Treg has been investigated by other laboratories, a 
detailed analysis has not been conducted thus far (Strauss et al., 2009; Singh et al., 
2010; Chai et al., 2002; Baatar et al., 2007). CD95L mRNA and protein can be induced 
by Treg to some extent indicating that the signaling machinery is functional but 
reduced (Fig. 3.1.1 and 3.1.3). Low CD95L expression in Treg at a time point at which 
Tcon express substantial levels of CD95L mRNA or protein could argue for a distinct 
regulation of CD95L expression in Treg. Therefore, different factors that might 
account for the low CD95L expression in Treg were investigated.  
The Treg population in human adults contains a high percentage of effector/memory 
cells, whereas the Tcon population comprises more naïve cells. Hence, CD95L 
expression in Treg might follow different expression kinetics compared to Tcon. Thus, 
CD95L expression at different time points after stimulation was examined in Treg. 
Regarding CD95L expression, it has been shown that pre-activated T cells can release 
CD95L from intracellular granules after very short stimulation periods (Schulte et al., 
2007). Effector/memory Treg are characterized by their pre-activated status and might 
therefore express CD95L after very short stimulation periods. However, short-term 
stimulation of Treg did not induce CD95L expression which indicates that Treg, 
despite being continuously activated by self-Ag in vivo, do not store CD95L to release 
it upon activation (Fig. 3.1.5).  
Treg did not increase CD95L after a very short stimulation period, however, CD95L 
expression in Treg might be present at different time points after stimulation 
compared to Tcon. To further investigate CD95L expression kinetics in Treg, cells 
were stimulated for an intermediate (10 hr) and a longer time period (40 hr). 
However, CD95L expression did not increase substantially in Treg at both time points 
while Tcon expressed high amounts of CD95L (Fig. 3.1.5). This excludes an 
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accelerated activation of the signaling machinery for the production of CD95L in Treg. 
The lack of CD95L after longer stimulation periods might be explained by a reduced 
or delayed stimulation-dependent signaling in Treg. A vast number of different 
stimulation-induced signaling molecules is required for the induction of CD95L 
transcription (Li-Weber and Krammer, 2003; Kavurma and Khachigian, 2003). Some of 
these molecules (phosphorylated Erk, Ca2+ influx) were shown to be reduced in Treg 
(Tsang et al., 2006). Furthermore, activated NF-AT, which is crucial for CD95L 
expression, is present in reduced amount in the nucleus of Treg compared to Tcon 
(Hickman et al., 2006).  
Not only the time point after stimulation might be decisive for CD95L in Treg, it is 
also possible that Treg do not express CD95L on day 0 and day 6 but on different days 
of in vitro culture. The investigation of stimulation-dependent CD95L expression on 
different days of culture (day 0 – day 6) demonstrated a low CD95L expression in 
Treg while Tcon were able to upregulate CD95L on all days of culture (Fig. 3.1.5). 
These results indicate that CD95L expression in Treg does not follow different in vitro 
culture kinetics. 
In addition, the involvement of the metalloprotease ADAM-10 in low CD95L 
expression by Treg was investigated. In total T cells, ADAM-10 plays a crucial role in 
the cleavage of CD95L protein from the cell surface (Schulte et al., 2007). Low CD95L 
on Treg might be caused by increased ADAM-10-mediated CD95L cleavage due to 
high ADAM-10 activity. However, incubation with an inhibitor of ADAM-10 during 
stimulation could not increae CD95L surface expression in Treg and minimally 
enhanced CD95L expression by Tcon compared to cells not treated with inhibitor (Fig. 
3.1.6).  
Collectively, the kinetics and inhibitor data demonstrate that CD95L expression in 
Treg is low irrespective of the time point of stimulation or in vitro culture and not 
caused by increased CD95L cleavage from the cell membrane. It can be concluded that 
CD95L expression by Treg is truly impaired.  
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4.1.4 The absence of Foxp3 increases CD95L expression in Treg 
The results obtained in this study demonstrate low CD95L expression by Treg on the 
mRNA as well as on the protein level. One factor that might be involved in the 
regulation of CD95L in Treg is the TF Foxp3 that is currently regarded as the most 
specific marker for the characterization of Treg (Feuerer et al., 2009). Although Foxp3 
seems to be negligible for the development of Treg, it is important for their 
suppressive function and metabolic fitness. Foxp3 has a dual function: on some 
promoters it acts as transcriptional activator while it represses the activation of others. 
For instance, Foxp3 together with NFAT enhances the transcription of CD25, while it 
downregulates the transcription of IL-2 (see Fig. 1.3.2). In addition, Foxp3 can also 
pair with other TF besides NFAT, e.g. Runx/AML1 and RORγt. The presence of Foxp3 
at the CD95L gene has been shown in a genome-wide Foxp3 target gene analysis 
(Zheng et al., 2007b). Therefore, it is possible that Foxp3 is directly involved in the 
repression of the CD95L promoter in Treg. To investigate the involvement of Foxp3 in 
CD95L expression, two experimental systems were employed. First, Foxp3 was 
transiently knocked down in human Treg. Second, GFP-labeled Foxp3-deficient Treg 
isolated from scurfy x DEREG mice were investigated. The combined use of two 
systems provides advantages over a single system. First, it allows the investigation of 
human and murine Treg. Second, although Foxp3 knock-down is not complete in 
human Treg, the effect of Foxp3 removal can be investigated in fully functional Treg; 
the murine system in contrast utilizes Foxp3- Treg and serves to investigate the 
complete lack of Foxp3. 
The investigation of stimulated Treg treated with siRNA against Foxp3 demonstrated 
an approximately doubled CD95L protein expression compared to scrambled siRNA-
treated Treg (Fig. 3.1.7). However, although CD95L expression was enhanced, it did 
not reach levels comparable to stimulated Tcon. One explanation for an elevated but 
still reduced CD95L protein expression in Foxp3-knocked down Treg compared to 
Tcon might be the residual Foxp3 protein. Despite efficient knock-down, 
approximately 20% of Foxp3 protein remained. This level might be enough to retain 
CD95L expression at a relatively low level.  
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In addition to the human Foxp3 knock-down studies, total CD4+ T cells isolated from 
scurfy x DEREG mice were stimulated and CD95L expression was investigated. 
Similar to human siFoxp3-treated Treg, Foxp3-deficient Treg displayed elevated 
CD95L expression compared to Foxp3-sufficient Treg (Fig. 3.1.9). In contrast to the 
human system, murine Foxp3-deficient Treg showed CD95L expression levels similar 
to stimulated Tcon. The difference in the expression levels observed between the 
human and the murine system could be explained by the residual Foxp3 protein in 
human Treg after Foxp3 knock-down and the complete lack of Foxp3 expression in 
murine Treg. The residual Foxp3 protein might strongly influence the upregulation of 
CD95L expression in human Treg. Nevertheless, the data obtained from the human 
and murine experiments demonstrate that CD95L expression is affected by Foxp3 in 
Treg.  
The obtained results do not clarify if Foxp3 is directly or indirectly involved in CD95L 
expression. The possibility remains that not Foxp3 itself but Foxp3-regulated factors 
hamper CD95L expression. These factors might still be present in Foxp3-knocked 
down Treg due to residual Foxp3 expression. As Foxp3 is not present at any time 
point in Foxp3-deficient murine Treg, Foxp3-regulated factors, e.g. TF like IRF6, are 
also absent (Zheng et al., 2007b).  
To obtain insight if Foxp3 is a direct regulator for CD95L expression, further 
experiments have to be carried out. CD95L-promoter luciferase reporter assays in the 
presence or absence of Foxp3 in Jurkat T cells have so far not been conclusive (data 
not shown). Therefore, chromatin immunoprecipitation as well as gel shift assays 
would be suitable methods to clarify if Foxp3 directly binds to the CD95L promoter.  
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Figure 1.4.1 │ The absence of Foxp3 results in stimulation-dependent CD95L 
expression by Treg. Foxp3-expressing Treg have low levels of CD95L surface protein 
whereas Foxp3 deficiency or knock-down results in elevated CD95L surface protein upon 
TCR stimulation.  
Foxp3 Foxp3
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4.2 In vivo experiments 
During immune responses Teff are crucial for the elimination of pathogens. However, 
they can also participate in the development of autoimmune diseases and immune 
pathology. During the past years, it has become clear that every immune response 
involves not only the recruitment and activation of Teff but also Treg. For the proper 
control of the quality and magnitude of immune responses and for establishing self 
tolerance, the Treg-mediated maintenance of the balance of the cell populations is 
crucial. Consequently, the importance of Treg in this process manifests in the severe 
multiorgan pathology and the fatal autoimmune syndrome developed by both mice 
and humans lacking the Treg-specific factor Foxp3 and therefore functional Treg 
(Schubert et al., 2001). In addition, depletion of Treg results in the activation of self-
reactive Teff and the development of autoimmune disease (Lahl et al., 2007; Kim et al., 
2007).  
Therefore, as Treg have to be present at the site of action in order to control Teff and 
other cell subsets, their homeostatic control constitutes a crucial factor. It is known 
that the CD95/CD95L system plays an important role in T cell homeostasis as both lpr 
and gld mice, harboring mutations in CD95 and CD95L, respectively, accumulate 
aberrant T cells. In the regulation of homeostasis of Treg, the role of the CD95/CD95L 
system remains controversial as gld mice have elevated Treg numbers while they do 
not seem to be affected in lpr mice (Mohamood et al., 2006; Zheng et al., 2007a). 
Therefore, a lack of data exists concerning factors and conditions that control Treg 
homeostasis. For this reason, the involvement of the CD95/CD95L system in the 
control of Treg homeostasis was investigated in vivo.  
4.2.1 Depletion of Treg by CD95 stimulation 
To investigate the involvement of the CD95/CD95L system in Treg homeostasis, a 
mouse model was established which enabled the examination of Treg death upon 
anti-CD95 mAb injection without killing the host by CD95-induced liver failure. 
RAG2-/- x lpr mice which lack functional CD95 (and tolerate anti-CD95 mAb 
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treatment) were reconstituted with BM isolated from either Foxp3.DGL (which give 
rise to CD95-sufficient T cells) or Foxp3.DGL x lpr mice (CD95-deficient T cells).  
After a BM reconstitution period of 6- 8 weeks, Treg of BM chimeric RAG2-/- x lpr 
mice were investigated. Examination of luciferase activity levels (which reflect Treg 
numbers) 24 and 48 hr after injection of anti-CD95 mAb demonstrated that Treg 
numbers in Foxp3.DGL  RAG2-/- x lpr mice had diminished compared to the 
beginning of the experiment (Fig. 3.2.3). In contrast, Treg numbers of Foxp3.DGL x lpr 
 RAG2-/- x lpr mice even increased proving that the depleting effect of the anti-
CD95 mAb was specific (Fig. 3.2.3). Interestingly, some Foxp3.DGL  RAG2-/- x lpr 
animals displayed stronger depletion of Treg than others. It is conceivable that the 
anti-CD95 mAb did not reach different tissues equally well and therefore only 
depleted Treg in specific organs. According to this, Treg numbers investigated by GFP 
measurement showed that GFP+ Treg decreased less in the spleen compared to LN 
(data not shown and Fig. 3.2.3 c).In addition, individual mice displayed a variable 
degree of chimerism reflected by a different amount of Treg numbers at the beginning 
of the experiments (Fig. 3.2.3 a, compare animal #1 with animal #3). This leads to a 
lower anti-CD95 mAb to Treg ratio in mice with better chimerism and could explain 
differences in individual mice. Furthermore, some mice had less Treg at 24 hr after 
injection while others had more reduced Treg numbers at 48 hr. It is possible that Treg 
depletion follows different kinetics in individual animals due to differential 
distribution of Treg or anti-CD95 mAb. Furthermore, a very restricted, but 
nevertheless lethal dose of anti-CD95 mAb (0.25µg/g body weight) was used. Future 
experiments could clarify if higher mAb doses might result in even better depletion of 
Treg (temporally as well as quantitatively).  
Although Treg numbers decreased upon injection of anti-CD95 mAb, approximately 
50% of Treg remained after anti-CD95 mAb injection. In humans, only 
effector/memory are sensitive to CD95-mediated apoptosis in vitro while 
resting/naïve Treg are resistant (Fritzsching et al., 2006). The Treg population in mice 
is heterogenous and contains effector/memory as well as resting/naïve cells. It is 
conceivable that only the effector/memory fraction of Treg is sensitive to CD95-
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induced apoptosis in vivo while the resting/naïve Treg population is resistant. 
Resting/naïve Treg would therefore be spared from depletion by anti-CD95 
engagement and explain the residual Treg population. Further experiments could 
clarify if the remaining Treg population is resting/naïve Treg which are less 
susceptible to CD95-mediated apoptosis in vivo. 
The presented data are in line with two publications which investigated CD95-
mediated apoptosis of Treg in different disease settings in vivo (Reardon et al., 2008; 
Chen et al., 2007). Chen et al. were interested in the effect of CD95-mediated depletion 
of Treg in the tumor environment. They engineered cancer cells to display CD95L on 
their cell surface. These cells could kill Treg at the tumor site while control cells could 
not. The depletion of Treg in this tumor model led to a decrease in tumor mass (Chen 
et al., 2007). In an additional study published in 2008, the authors investigated Treg 
numbers during drug-induced colitis (Reardon et al., 2008). They found that Treg 
were depleted from the inflamed tissue site by a yet unidentified cell type expressing 
CD95L at the decline of the infection. The mechanism of Treg depletion at the end of 
an immune response was only transient. However, it might be a short-term 
mechanism which allows robust pathogen-clearing immune responses following 
localized insult and injury.  
The data obtained in this thesis demonstrate that Treg are sensitive to CD95-mediated 
apoptosis in vivo. In addition, they show for the first time that Treg can be depleted 
systemically in healthy non-infected mice by CD95 crosslinking. Together with the 
two studies mentioned above, the data demonstrate that Treg are not only sensitive to 
CD95-induced apoptosis during ongoing inflammation but also in non-infected 
animals. This suggests that CD95-mediated apoptosis is a mechanism for the 
homeostatic control of Treg in vivo. Although the CD95L+ cell type remains elusive, it 
can be hypothesized that Teff, which express CD95L during the peak and the 
contraction of an immune responses, could kill CD95-sensitive Treg (Fig. 1.4.2), 
thereby enhancing the immune response. As explained above, this mechanism might 
ensure the complete elimination of pathogens that would persist if Treg-mediated 
suppression was already active at an earlier time point of the immune response. In 
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that context it was shown that CD4+ Tcon could kill Treg in a CD95-dependent 
fashion in vitro (Strauss et al., 2009). However, the CD95L+ cells will decline after 
clearance of the pathogen, allowing Treg to repopulate the intestine and probably help 
to end the immune response. In the context of autoimmune disease, however, a 
constant elimination of Treg by hyperactivated self-reactive Teff via CD95-mediated 
apoptosis could result in a hyperactive immune system.  
 
 
 
 
 
 
Figure 1.4.2 │ Treg numbers might be regulated by CD95L-expressing Tcon 
during immune responses. At the beginning of an immune response, Tcon and Treg 
numbers are in an equilibirium. During the peak and contraction, Tcon express CD95L by 
which Treg and some Tcon are eliminated. This shifts the balance towards the 
pathogen-clearing Tcon. At the end of the immune response, the balance between both 
cell populations is reestablished. 
start peak contraction
T cell-mediated immune response
end
Tcon Treg
CD95
CD95L
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4.3 Outlook 
Treg depletion is being used as therapy for different diseases in which elevated Treg 
numbers have been reported to be disadvantageous for clinical outcome. Currently, 
CD25-mediated depletion of Treg is used in the clinic for the treatment of different 
types of cancer (Waldmann, 2007; Mahnke et al., 2007b).  
The findings presented in this thesis open up the possibility to use CD95-mediated 
Treg depletion as novel therapeutic strategy. As the systemic use of anti-CD95 mAb 
would lead to liver failure in human patients, a particular therapy has to be 
considered. The finding of a Treg-specific surface marker would allow the application 
of a bispecific mAb targeting the Treg surface molecule and CD95 to specifically 
deplete Treg. In conclusion, the presented data might provide the basis for the 
development of new and powerful therapies.  
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5 List of abbreviations 
 
ADAM-10 a disintegrin and metalloprotease 
Ag antigen(s) 
AICD activation-induced cell death 
ALPS autoimmune lymphoproliferative syndrome 
APC  antigen presenting cell  
Bcl-2 B cell lymphoma 2 
BM bone marrow 
mAb  monoclonal antibody  
caspase cysteine-aspartic acid protease 
CD cluster of differentiation 
CD95L CD95 ligand 
c common  chain 
d  day 
DC dendritic cell(s) 
DD death domain 
DEREG mice depletion of Treg mice 
DISC death-inducing signaling complex 
DMSO  dimethyl sulfoxide 
DN double negative 
DP double positive 
DT diphtheria toxin 
DTR diphtheria toxin receptor 
FACS  fluorescence activated cell sorter 
FASER fluorescence amplification by sequential employment of reagents 
FCS  fetal calf serum  
cFLIP cellular FLICE inhibitory protein 
Foxp3  Forkhead Box P3  
Foxp3.DGL mice Foxp3.DTR-GFP-luciferase mice 
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GFP green fluorescent protein 
gld generalized lymphoproliferative disease 
GvHD graft vs. host disease 
Gzm granzyme 
hr  hour  
IL  interleukin  
IPEX immune dysregulation, polyendocrinopathy, enteropathy x-linked 
LN lymph node(s) 
Lpr lymphoproliferation 
MACS  magnetic activated cell sorter  
MHC  major histocompatibility complex  
min minute(s) 
NF-AT  nuclear factor of activated T cells  
NF-κB  nuclear factor κ B  
NK natural killer 
PAMP pathogen-associated molecular pattern(s) 
pb plate-bound 
PBL peripheral blood leukocyte(s) 
PCR polymerase chain reaction 
PBS  phosphate buffered saline  
RAG2 recombinase activating gene 
rpm  revolutions per minute  
RLU relative light unit(s) 
mRNA  messenger ribonucleic acid  
Tcon  conventional T cell(s)  
TEC  thymic epithelial cell  
Teff  effector T cell(s) 
TF transcription factor 
tg transgenic 
TGF-β  transfoming growth factor-β  
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TLR  toll like receptor  
Treg  regulatory T cell(s) 
nTreg naturally occurring Treg 
TCR  T cell antigen receptor  
IU  International Unit  
wt wild type 
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